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ABSTRACT: 
Title : Study of results following isolated loop pancreatico jejunostomy after classical 
whipples procedure: Results of 38 cases  
AIM:To analyse the results in terms of morbidity and mortality following isolated loop 
pancreaticojejunal anastomosis and to look for difference if any between duct to mucosa 
versus dunking type of anastomosis. 
To evaluate results in terms of morbidity and mortality from isolated loop pancreaticojejunal 
anastomosis and compare with results from anastomosis using single jejunal loop and 
pancreaticogastrostomy.  
MATERIALS AND METHODS: 
All patients attending the outpatient department of Surgical Gastroenterology with operable 
growth in the periampullary region or head of pancreas were included in the study group. The 
data of one hundred and thirty eight patients were collected prospectively. Details tabulated 
included demographic characters, preoperative variables , performance status , diagnosis 
,type of anastomosis , postoperative morbidity  and mortality .Postoperative morbity noted 
included  delayed gastric emptying , anastomotic leak , hemorrhagic complications ,wound 
infection , intraabdominal collection , pneumonitis and urinary tract infection .All patients in 
the study underwent a standard whipple’s pancreaticoduodenectomy.  
 
 RESULTS:  
Of the male and 38% were female patients. The minimum age was 30 and maximum one 
hundred and thirty eight patients included in the study 62% were age was 72 with a mean age 
of 51.7. The distribution of disease were as follows: periampullary 102[79.68%], pancreatic 
15[11.7%], distal CBD 6[6%] and duodenal growth 5[4.6%].Among the complications 
delayed gastric emptying occurred in 57[44.53%], haemorrhage in 7[5.4%], pancreatic leak 
in 30.46%( grade A-20 [15.6%], grade B-12 [9.3%], and grade C-7[5.4%]), intraabdominal 
collection in 15%, wound infection in 22%, pneumonitis in 7%, urinary tract infection in 6% 
of patients. The incidence of delayed gastric emptying in the PG group was 38.46% , the 
incidence in the PJ group was 40.98% and in the isolated loop pancreaticojejunostomy group 
was 44.73%.The incidence of haemorrhage was 7.6% in the PG group, 6.5% in the PJ group 
and nil in the isolated PJ group . The incidence of pancreatic anastomotic leak between the 
three groups was  33% in the PG , 29.5% in the PJ group and 15.78%  in isolated PJ group. 
The incidence of intra abdominal collection in the PG group was 7[17.9%], in the PJ group it 
was 7 [ 11.4%] and in the isolated PJ group was 5 [13.15%]. The incidence of wound 
infection was 20.8% in the PG and 26.9% in the PJ group and 22% in isolated PJ group. The 
incidence of pneumonitis in the PG group was 2 [5.1%] compared to 4[6.5%] in the PJ group 
and 3[7.8%] in Isolated PJ group. The incidence of urinary tract infection in the PG group 
was 1[2.5%] and in the PJ group it was 2[3.2%].and 1 [2.6%] in  isolated  PJ  group. The 
mean duration of nasogastric tube removal was 7.5 days in the PG group and 7.8 days in the 
PJ group and 7.0 in Isolated PJ group. The mean days of urinary catheter removal was 6.3 
days in the PG and 6.7 in the PJ  group and 8.0 in isolated PJ group. The mean days of 
drainage tube removal was 9.3 days in the PG and 9.9 days in the PJ group and 11 in the 
isolated loop PJ group. The mean postoperative hospital stay was 12.6 days in the PG group 
and 13.1 days in the PJ group and 11.2 in isolated PJ group.The mortality in the patients who 
underwent pancreaticogastrostomy was 5.1% ,in the pancreaticojejunostomy group was 4.9 
%and  7.8 %in isolated loop PJ .The overall mortality rate was 5.79%. 
Discussion : Among the 138 patients 57 patients developed DGE,   21 patients developed 
DGE and pancreatic leak and  15 patients developed other complications along with DGE and 
pancreatic leak accounting for a morbidity of 39.28%. 38 % of patients in the PG group and 
40.98 % in the PJ and 44.73% group developed DGE. The increase in DGE with isolated 
loop was statistically significant (P value=0.052, 0.045).Pancreatic leak occurred in 39 
patients with grade A leak in 20(14%), grade B leak in 12(8.6%) and grade C leak in 7(5%) 
patients. All patients with pancreatic leak were managed by non-operative means. There was 
no statistically significant difference in the incidence of anastomotic leaks among three types 
of anastomosis , though isolated loop  pancreaticojejunostomy tended to have more type A 
leaks .No hemorrhagic complications were seen with isolated loop pancreaticojejunostomy. 
There was no significant difference in incidence of other major morbidities.The mortality rate 
in our study was5.7 % (5.1% in PG group and 4.9% in PJ grou,7.8% in isolated loop PJ 
group) which was not statistically not significant (P value=1.07,1.12) between the three 
groups.  
Conclusion:In comparison to pancreatico gastrostomy or single loop pancreatico 
jejunostomy, Isolated loop pancreatico jejunal anastomoses might lead to lower incidence of 
higher grade of pancreatic leak .Both dunking and duct to mucosa type anastomoses seem to 
have similar incidence of leaks , in all three type of anastomosis .There is no significant 
difference in mortality rate between the three types of pancreaticoenteric anastomosis 
.However , incidence of higher grade leak and anastomotic leak related mortality is lower 
with isolated loop  anastomosis  .Incidence of delayed gastric emptying seems to be higher 
and  hemorrhagic complications rarer with isolated loop pancreaticojejunal anastomosis  
compared to other types of pancreaticoenteric anastomosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1INTRODUCTION
Pancreaticoduodenectomy (PD) is the procedure of choice for
treatment of peri-ampullary and pancreatic head malignancies and was first
described by Allen Whipple et al [1] in the 1930s. Early enthusiasm
concerning the procedure was followed by scepticism because of the
associated high morbidity and mortality rates2. However advances in
operative techniques and perioperative patient care have resulted in lower
hospital mortality and longer Survival, making the procedure relatively
safe in expert hands. [3, 4].
Despite recent favorable outcomes, leakage from the pancreatic
stump anastomosis is still considered a significant source of morbidity and
associated mortality. Various methods of surgical management of the
pancreatic remnant have been proposed to address this serious problem.
The  rationale  of  creating  an  isolated  Roux  loop  for  the  drainage  of  the
pancreatic stump was first introduced by Machado et al [5] in  1976.  They
proposed that this isolated Roux loop can prevent the activation of
pancreatic fluid by the intestinal contents and bile, and therefore protect
the pancreaticojejunal anastomosis from erosion.
2The  aim  of  this  study  was  to  assess  the  results  of  the
pancreaticojejunal anastomosis formed with an isolated Roux loop
compared to the standard single loop technique pancreaticojejunostomy
and pancreaticogastrostomy.
3AIM
To analyse the results in terms of morbidity and mortality following
isolated loop pancreaticojejunal anastomosis and to look for difference if
any between duct to mucosa versus dunking type of anastomosis.
To evaluate results in terms of morbidity and mortality from isolated
loop pancreaticojejunal anastomosis and compare with results from
anastomosis using single jejunal loop and pancreaticogastrostomy.
4REVIEW OF LITERATURE
Periampullary cancer includes adenocarcinoma of the head, neck,
and uncinate process of the pancreas, ampulla, distal common bile duct
and ampullary duodenum. Often, the precise site of origin cannot be
determined until the tumour has been resected[1]. Pathologic examination
of resected pancreaticoduodenectomy specimens reveal that 40–60% are
adenocarcinomas of the head of the pancreas, 10–20% are
adenocarcinomas of the ampulla of Vater, 10% are distal bile duct
adenocarcinomas, and 5–10% are duodenal adenocarcinomas. Since these
data represent resected specimens, and since the resectability rate of the
nonpancreatic periampullary cancers is much higher, it is likely that
pancreas is the site of origin in up to 90% of cases[2].
HISTORY
Of the many indications for pancreatic resection, cancer has been the
most intensely researched and the most meticulously documented. Ductal
adenocarcinoma is the most common tumor of the pancreas,with a
predominant site of origin being the pancreatic head (78%) [3]. Pancreatic
resection is deemed to be one of the most complicated and technically
challenging surgical procedures[5].The study of the history of pancreatic
surgery also offers insight into the evolution of the surgical techniques.
5Pancreaticoduodenectomy probably had its origins in papillectomy, with
Halsted (1899) being the first to report a successful resection of the
ampulla in 1898. This accomplishment emboldened other investigators to
experiment with more extensive excisions of the ampulla, duodenum and
pancreas. Also in 1898, Codivilla (1898) reported the first
pancreaticoduodenectomy, which he had performed in one stage. His
patient died on the 21st postoperative day, however, from complications
arising from what seemed like a pancreatic leak [4]. The first successful
pancreaticoduodenectomy was performed by a German surgeon, Kausch,
11 years after Codivilla’s landmark effort [5]. Kausch,  a  student  of  Von
Mickulicz-Radecki, performed the operation in two stages. In the first, he
decompressed the biliary tree, and 6 weeks later, he completed the
extirpation and the reconstruction, including a pancreaticoduodenal
anastomosis to the third part of the duodenum. In their 1935 landmark
publication, Whipple and co-workers reviewed their series of 80 patients
who had surgical treatment for ampullary carcinoma, among which were 2
cases of pancreaticoduodenectomy. Whipple’s maiden attempt was a two-
stage procedure, with biliary and gastric decompression in the first stage
and tumor extirpation in the second stage. With increasing experience.
Whipple’s technique eventually evolved into a one-stage procedure
complete with a pancreaticojejunostomy[6  ]. This metamorphosis was
6bolstered by the discovery of Vitamin K in 1929 and the “fat metabolizing
hormone” in 1936. His one-stage innovation ensured a clean surgical field
devoid of scars and adhesions that were the trademarks of a preliminary
operation. In tribute to his efforts in this seminal work, Hunt (1941)
labelled this method Whipple’s procedure[7].Even with improvements in
multimodality treatment, surgery remains a crucial centrepiece of the
treatment algorithm for pancreatic cancer as there is  no truly effective
chemotherapeutic agents for treating nonresectable disease developed yet.
The American Gastroenterological Association (1999) endorsed
pancreaticoduodenectomy as the recommended operation for patients with
resectable tumours. Technical improvements have led to the advent of a
number of different types of surgical techniques that allowed a more
individualized, disease-directed approach. These modifications were
responsible in part for the decrease in surgical morbidity.
EPIDEMIOLOGY AND RISK FACTORS
In 2004, an estimated 31,270 deaths were attributed to pancreatic
cancer, making it the fourth leading cause of cancer mortality in the Unites
States[10] .There is a slightly higher incidence in men than in women
(relative risk 1.35) and in African American men (30-40% higher).
Advancing age is perhaps the stronger risk factor. The peak incidence of
7pancreatic cancer is in the 60s and 70s, and mean age at diagnosis is 60 to
65  years  [11]. Other risk factors include Ashkenazi Jewish heritage,
cigarette smoking, diabetes mellitus, chronic pancreatitis, obesity, low
level of physical activity, and occupational exposure to carcinogens. Six
genetic syndromes have been linked to pancreatic adenocarcinoma:
hereditary pancreatitis, hereditary nonpolyposis colorectal cancer,
hereditary breast and ovarian cancer, familial atypical multiple mole
melanoma syndrome, Peutz-Jeghers syndrome, and ataxia telangectasia.
The relationship between diabetes, pancreatitis, and pancreatic cancer is
complex and controversial because pancreatic cancer itself can cause
pancreatitis and Hyperglycemia, through destruction of the pancreatic
parenchyma and other poorly understood mechanisms [12].
CLINCIAL PRESENTATION
Because most pancreatic cancers arise in the right side of the gland,
the hallmark of clinical presentation for periampullary and pancreatic
cancer is jaundice, resulting from obstruction of the intrapancreatic portion
of the common bile duct. The jaundice is often progressive and associated
with dark urine, light stool, and pruritus. Although some patients exhibit
vague, intermittent epigastric pain, locally advanced pancreatic cancer with
8tumour invasion of the celiac plexus typically causes a constant dull
epigastric pain, often accompanied by back pain.
In 15% to 20% patients with pancreatic cancer, new-onset diabetes
mellitus is observed. The suspicion of pancreatic carcinoma should be
raised in patients older than 60 years who develop mild diabetes. Similarly,
the possibility of a pancreatic neoplasm causing partial pancreatic duct
obstruction should be considered in elderly patients with newly diagnosed
pancreatitis, particularly in the absence of cholelithiasis and ethanol abuse.
Obstruction of the pancreatic duct also may cause pancreatic exocrine
insufficiency, manifested by malabsorption and steatorrhea. Nonspecific
symptoms, such as nausea, anorexia, weight loss, and fatigue, are common
in many patients  with periampullary cancer.  Obstruction of  the C loop of
the duodenum and at the ligament of Treitz can develop as a result of local
tumour involvement from the periampullary region and midbody of the
pancreas. At initial presentation, the most common physical finding is
jaundice. Evidence of cutaneous scratching is commonly present,
secondary to the pruritus [9].
Patients with metastatic pancreatic cancer may exhibit left
supraclavicular adenopathy (Virchow’s node), ascites, palpable hepatic
metastases, periumbilical lymphadenopathy (Sister Mary Joseph’s
9nodules), or drop metastases surrounding the perirectal region (Blumer’s
shelf).
Laboratory analysis often reveals elevated liver function studies,
reflecting the degree of biliary obstruction. Hyperglycemia is commonly
seen, but the mechanism for this is unclear. In deeply jaundiced patients
with malabsorption of fat-soluble vitamins, prolongation of the
prothrombin time may be seen.
Serum carbohydrate antigen 19-9 (CA 19-9) may be elevated;
however, this tumour marker is neither sensitive nor specific for pancreatic
cancer because 15% of patients do not secrete CA 19-9 owing to their
Lewis antigen status. CA 19-9 levels may not be elevated early in the
disease. Using a cut-off of 37 U/ml, the sensitivity and specificity for
pancreatic ductal adenocarcinoma have been reported to be 81% to 85%
and 85% to 90% (Tamm et al, 2003). Levels greater than 120U/ml have
been predictive of metastatic disease (Cooperman, 2001). The main value
of CA 19-9 is in follow up of patients after curative resection and in
monitoring their response to chemotherapy. [10]
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DIAGNOSIS AND ASSESSMENT OF RESECTABILITY
The aim of clinical staging is to define disease extent reliably, so as
to avoid unnecessary intervention and the accompanying morbidity,
mortality and diminished quality of life in patients with advanced
disease[13]. Although clinical trials use TNM staging system most often, in
practice physicians conventionally the disease as resectable, locally
unresectable and metastatic disease [14]. Resectable pancreatic cancer is
universally defined, based on preoperative workup, as a pancreatic tumour
without involvement of the superior mesenteric artery or the celiac axis, a
patent superior mesenteric-portal venous confluence, and no evidence of
distant metastasis [15]. Portal vein involvement is controversial, and
resectability often depends on the operating centre. Imaging is the
mainstay for diagnosis and staging of pancreatic tumours, as against the
traditional approach of surgical exploration and intraoperative evaluation
to determine resectability.
COMPUTED TOMOGRAPHY
Helical computed tomography (CT) has been established as the most
efficacious initial staging study [16] and often is used as the entry point to a
management algorithm. The experience, cost, popularity, and ease of
interpretation favour helical CT as the most sensitive initial test to
11
diagnose and stage pancreatic cancer [17].Multiplanar three-dimensional
reconstructions can provide involvement of vascular structures and the
degree and level of dilation of the pancreatic and biliary ducts [18].
Although the superior mesenteric vein is best seen with axial cuts, sagital
reformatting is best for showing superior mesenteric artery involvement
[19]. Coronal reformatting can show possible tumour extension into the
adjacent duodenum or stomach. Duodenal assessment is enhanced further
with the use of a negative oral contrast agent such as water.
Regarding resectability, spiral CT scan has been reported to have a
positive predictive value of 100%, negative predictive value of 56%,and
overall accuracy of 70% for unresectable pancreactic carcinoma [19].This
ability to predict unresectability preoperatively is superior to the ability to
predict resectability, particularly because the detection of small (<5mm)
liver and peritoneal metastases is limited even with today’s CT technology.
Vascular involvement is the next most common reason for unresectability.
Tumour encasement is inferred from narrowing or obliteration of vascular
lumen, and radiologic grading criteria have been developed for
circumferential vessel involvement [20, 21]. Generally if the tumour
surrounds more than half the circumference of a named vessel, it is
deemed unresectable. Additional radiologic features that suggest vascular
invasion include perivascular cuffling, described as increased attenuation
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of the normal perivascular fat, and the presence of dilated collateral veins.
The “teardrop” sign, which describes the deformity of the otherwise round
shape of the superior mesenteric vein, suggests venous invasion[22]. An
added bonus afforded by the excellent overview of pertinent anatomy and
structures is the se of the multidetector CT as a valuable preoperative
planning tool [23].
MAGNETIC RESONANCE IMAGING & MRCP
Magnetic resonance imaging (MRI) has been compared extensively
with CT for the detection of vascular invasion and distant metastases, and
most studies have shown equivalent accuracy between the two
modalities[24]. MRCP is non-invasive and delineates the pancreatic and
biliary ducts. It detects pancreatic or ampullary carcinoma by showing the
effect of a space occupying lesion on the ducts – obstruction or
displacement. The classic feature is the “double duct” sign. A strictly
defined double-duct sign is only 80% to 85% specific for malignancy,
however (Menges et al, 2000).Other recent advances include secretin-
enhanced MRCP, which can improve pancreatic duct and side branch
delineation. Such pharmacologic stimulation of pancreatic juice secretion
allows the evaluation of pancreatic flow dynamics and assessment of
pancreatic exocrine function [19].
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ENDOSCOPIC ULTRASOUND
In detecting small lesion (<20 mm), EUS is more sensitive with a
sensitivity of 93% to 100%. A meta-analysis of studies comparing staging
by EUS with other modalities reported that EUS (without fine-needle
aspiration) more accurately predicted T stage, N stage, and portal vein
involvement than CT. One of the greatest attributes of EUS is the ability to
perform EUS-guided fine-needle aspiration of the primary tumour and the
regional lymph nodes without the risk of tumour seeding along the needle
tract, as opposed to the percutaneous technique [26]. EUS guided fine
needle aspiration is only of diagnostic value, however, if histology
confirms a pancreatic tumour. The major limitations of this technology are
that results are operator dependant and a limited visualization afforded for
the detection of distant metastasis.
ERCP
The  emergence  of  MRCP,  EUS,  and  multidetector  CT  with
multiplanar three-dimensional reconstruction has reduced the role of
endoscopic retrograde cholangiopancreatography (ERCP) as a diagnostic
tool.  Besides  the  ever  present  risk  of  pancreatitis,  the  use  of  ERCP in  an
obstructed system might induce cholangitis. A normal pancreatogram does
not equate absence of malignancy, and this can occur in approximately
14
20% of patients with pancreatic cancer. Potential “blind spots’ on ERCP
include the uncinate process, the accessory duct, and the tail. In a study
comparing ERCP with MRCP in evaluating patients with suspected
malignant bile duct obstruction, it was found that the presence and site of
the biliary stenosis were assessed correctly in 100% of cases using MRCP,
as opposed to 95% with ERCP[27]. MRI has an additional advantage given
its ability to provide cross-sectional anatomic evaluation of the upper
abdomen.
POSITION EMISSION TOMOGRAPHY
Position Emission Tomography (PET) is being used to detect the
primary malignant tumour, to detect regional and distant metastases, to
differentiate benign disease from malignant disease or recurrent cancer
from treatment-related scarring, and to document response to therapy [28].
An extensive review of the FDG PET literature in the year 1993-
2000 stated, the overall sensitivity and specificity of FDG PET as an
oncologic imaging tool at 84% and 86%, respectively.FDG PET has been
found to be more accurate than other imaging methods in detecting
pancreatic cancer. It is especially useful in localizing the disease when CT
is equivocal owing to treatment-related anatomic alteration [29]. PET
provides an alternative in tumours less than 2 cm in diameter. By changing
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the radiotracer to carbon 11-labeled 5-hydroxyl L tryptophan, PET
imaging also has found a niche in the detection of neuroendocrine tumours.
5-Hydroxyl-L-tryptophan PET has been reported to be better than CT and
somatostatin receptor scintigraphy for tumour visualization and has
allowed the detection of many small, previously overlooked lesions. PET
is not without pitfalls. False negative results are reported in patients with
hyperglycemia, patients with very early stage cancer and in well-
differentiated tumors.Limited spatial resolution and the absence of
anatomic landmarks make PET inferior to CT in assessing surgical
resectability, in particular, vascular encasement. It is believed that PET
performed in isolation has only a limited role in the workup of pancreatic
cancer. The findings should be correlated with CT scans to obtain
complementary information. This need has led to the development of
hybrid PET-CT scanners, a combined physiologic and anatomic diagnostic
modality.
DIAGNOSTIC LAPAROSCOPY
Diagnostic laparoscopy was introduced as a minimally invasive
strategy for the detection of peritoneal carcinomatosis and liver metastases
to avoid unnecessary laparotomies in patients with advanced disease. Used
in conjunction with helical CT, laparoscopic assessment can have a
16
positive predictive value of 100%, a negative predictive value of 91% and
an overall accuracy of 94% [30]. Laparoscopic ultrasound was added as an
adjunct to laparoscopy to allow the detection of intraparenchymal lesions
and vascular invasion or encasement. With ultrasound, the accuracy of
determining resectability is improved to 98%. Advocates have reported
that laparoscopy can identify occult metastases, which were not detected
by a preceding CT scan, in 30% of patients. Consequently the resection
rates after laparoscopy have been reported to be 75% to 95%. Because of
these results, some centres strongly recommend the use of diagnose
laparoscopy as a routine procedure. But the same is not justified [31] and
laparoscopy is performed for patients at high risk of occult metastatic
disease and in whom a palliative procedure is not required. In addition,
laparoscopy can be performed for patients with ascites, larger primary
tumours, and who’s clinical or laboratory findings suggest an already
advanced disease [31].
STAGING
Currently, only a few patients with pancreatic cancer are candidates
for surgical resection, the only potentially curative therapy. In most
patients, accurate preoperative staging of periampullary and pancreatic
cancer is achieved by multidetector CT with three dimensional
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reconstruction. A resectable tumour is characterized by lack of evidence of
metastatic disease, a clear tissue (fat) plane between the tumour and
visceral arteries (celiac axis and superior mesenteric artery), and less than
or equal to 180-degree-circumferential involvement of the superior
mesenteric vein-portal vein confluence. In contrast, in unresectable disease
,there is distant metastases, ascites, involvement of the superior mesenteric
artery or celiac axis, or total occlusion of the superior mesenteric vein-
portal vein confluence. Using three-dimensional CT to stage patients who
subsequently underwent laparotomy for periampullary cancer, 98% of
patients with three-dimensional CT scans interpreted unequivocally as
resectable underwent resection. For patients with nondefinitive three-
dimensional CT criteria of unresectability (e.g., questionable superior
mesenteric artery involvement or near-complete superior mesenteric vein-
portal vein encasement with preserved patency), only 22% underwent
resection. Patients with no definitive radiographic criteria for
unresectability should not be committed to nonoperative therapy.
TREATMENT
Surgical resection remains the only potentially curative therapy for
periampullary and pancreatic cancer. Only a few patients currently
diagnosed with pancreatic cancer are candidates for curative resection. It is
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hoped that as programmes for early detection improve and gain widespread
use, the percentage of patients who are candidates for resection will
Increase. Approaches for resection are based on tumour location and
extent. Resection of right-sided tumours typically requires
pancreaticoduodenectomy. In many instances, preoperative biliary
decompression is unnecessary and may result in increased postoperative
complications [32].
Selected patients with biliary sepsis, advanced malnutrition, or
significant time delay before surgery may benefit from preoperative biliary
decompression, which can be accomplished endoscopically with a plastic
endoprosthesis in most instances. If endoscopic decompression cannot be
accomplished, placement of a percutaneous transhepatic biliary drainage
catheter can be pursued.
PREOPERATIVE MANAGEMENT
Preoperative Workup and Preparation
General
Pancreatic resection surgery imposes a significant physiologic stress
on patients. Most patients are elderly (the peak incidence of pancreatic
cancer falls in the 65-75 year age group) [33]. In such patients, there also is
a higher incidence of comorbidities.
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Cardiopulmonary exercise testing and lung function testing can
evaluate examine accurately the capability of the cardiorespiratory system
for oxygen delivery under stress and the need for postoperative ventilator
support. Weight loss and dehydration are frequent features of patients with
pancreatic disease, and in such patients, the initial effort is to maximize
preload. Optimization of after load and myocardial contractility is equally
important, and occasionally, may need insertion of pulmonary artery
catheters.
Before any major procedure involving resection, the patient’s  blood
is matched for 2 units. Routine blood investigations and serum tumour
marker assay, specifically CA 19-9 are done.
A prophylactic dose of low molecular weight heparin to patients,
begun the evening before the day of surgery and continued till the patients
are ambulant post operatively is advised. In addition, patients wear
compression stockings, intraoperatively and for their entire inpatient stay.
Stockings act by reducing pooling of blood in deep veins by mechanically
preventing venous distension and are a simple, inexpensive method of
deep vein thrombosis prophylaxis. Antibacterial prophylaxis has been
instrumental in the reducing infection-related morbidity in clean
contaminated procedures. It is recommended for all patients undergoing
20
hepatobiliary or pancreatic surgery. Drugs with anti anaerobic activity are
added if there is an anticipated encounter with anaerobes during the
procedure, in particular, with procedures involving the gastrointestinal
tract. Guidelines recommend the highest licensed dosage of the chosen
antimicrobial agent. This agent should be given intravenously at induction
of anesthesia to achieve high peak tissue concentration at the site of the
wound before the first incision and should be maintained until the time of
closure. Re-dosing should be done when the procedure lasts more than 2
antibiotic half-lives. In all procedures in which the biliary tract is entered,
the bile is sent for antimicrobial culture and sensitivity to guide
postoperative antimicrobial treatment should this need arise.
Pancreatic cancer is notorious in its association with significant
metabolic and nutritional disturbances. Weight loss of 10% or more is well
known to affect outcome adversely with an overall increased susceptibility
to postoperative complications. Clinical trials addressing the role of
preoperative nutritional therapy have found no reduction in morbidity or
mortality using either total parenteral nutrition (TPN) or enteral nutrition.
The controversy is fuelled further by the observation that the surgical
mortality or morbidity has decreased significantly without emphasis on
prior perioperative nutrition. Perhaps only patients with severe
malnutrition, in particular patients with physiologic impairment, would
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have a tangible benefit from perioperative and postoperative nutritional
support [35].
Patients in whom, for some reason, surgical extirpation has to be
delayed and have a demonstrable loss of weight, or patients with severe
malnutrition with physiologic dysfunction are candidates for nutritional
support. The latter group can be identified using physiologic function tests,
such as hand grip strength. Even lung function testing can serve as a
simple assessment for voluntary muscle function. Serum markers, such as
transferrin, prealbumin and retinol binding protein, also are invaluable in
confirming significant malnutrition. These are more accurate than albumin
as a marker of nutritional well-being. If perioperative nutritional support is
required, the enteral route is preferred.
ROLE OF SOMATOSTATIN
The pancreaticoenteric anastomosis has been deemed the “Achilles
heel” of pancreaticoduodenectomy because of the potential for disastrous
consequences of life-threatening intra-abdominal sepsis and haemorrhage
that may follow a pancreatic leak. Based on the findings of the trials
conducted by Buchler et al, 1992 & Friess et al, 1995 all patients
scheduled for pancreatic resections, were given a prophylactic
subcutaneous octreotide (Sandostatin), beginning with the first dose of 200
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?g given at induction. If the pancreas is thought to be high risk by the
surgeon, because of a soft consistency or a pancreatic duct size of less than
3 mm in diameter, the post surgical regimen would be three daily doses of
200 ?g of octreotide for the next 5 days. Conversely, if the gland is firm
with a relatively wide duct, each individual dosage would be 100 ?g.
ROLE OF PREOPERATIVE BILIARY DRAINAGE
 Patients with pancreatic or periampullary cancer who have jaundice
are at risk of developing coagulopathy, malabsorption, malnutrition, and
immune dysfunction. There have been at least two meta-analyses
published on this subject. Sewnath and colleagues (2002) found that there
was no significant difference in the overall death rate between patients
who had preoperative biliary drainage and patients who had surgery
without preoperative biliary drainage [38]. Instead, the overall
complication rate was significantly adversely affected by preoperative
biliary drainage. The length of in hospital stay also was increased. The
investigators concluded that preoperative biliary drainage has no benefit.
In a more recent review, Saleh and associates (2002) found no evidence of
either a beneficial or an adverse effect of preoperative biliary stent
placement on the outcome of surgery in patients with pancreatic cancer
[39]. The role of preoperative biliary drainage in patients with biliary
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obstruction undergoing pancreatic resection is controversial at best. What
is clear is that endoscopic drainage is better than percutaneous methods. So
preoperative biliary drainage, as a routine practice, is not warranted
.Rather,  it  can  be  done  for  patients  with  cholangitis  or  other  severe
complications of jaundice that would preclude a safe resection. Another
indication would be jaundiced patients requiring neoadjuvant
chemotherapy before surgical extirpation.
EPIDURAL ANALGESIA:
Studies on “fast track” gastrointestinal surgery have demonstrated
that epidural analgesia, given along with an intensive, standardized
regimen of early feeding and mobilization reduces hospital stay [40].
Epidural analgesia has many benefits, including a shorter duration of
postoperative ileus, decrease in magnitude of the stress response, lesser
pulmonary complications, better postoperative pain control and improved
mobility. Thoracic epidural analgesia is of particular benefit in  patients
with  a  high  risk  of  cardiac  or  pulmonary  morbidity  and  reduces  the
duration of hospital stay and  hospital costs in this subgroup of patients.
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OPERATIVE MANAGEMENT
Panceraticoduodenectomy
Technique
The patient’s abdomen is cleansed from the nipple level down to the
level  of  the  symphysis  pubis,  and  the  operative  field  is  squared  off  with
sterile drapes. By either a midline or roof-top incision peritoneal cavity is
entered. The ligamentum teres and the adjoining falciform ligament are
routinely divided to facilitate a thorough examination of the liver. The
peritoneal surfaces including pelvis and root of mesentery are inspected
carefully for metastatic deposits. Resection is preceded only if there is no
evidence that would preclude an R0 resection.The lesser sac is entered by
dividing the gastrocolic ligament. On the left side, the gastrocolic ligament
is divided up to the most medial branch of the short gastric vessels. This
ensures an alternative venous egress for the splenic blood flow in case of
requirement of venous resection of the superior mesenteric vein-portal vein
trunk. Moving toward the right, caudal mobilisation of the hepatic flexure
is done .Meticulous and safe dissection in the avascular plane in-between
the hepatic flexure and the duodenum and an extensive Kocher manoeuvre
is done .This allows freeing of the the third part of the duodenum from the
colonic mesentery. The gastrocolic trunk of Henle is encountered here, and
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tracing it down leads to the superior mesenteric vein. Alternatively, the
superior mesenteric vein can be identified through a Cattell Braasch
maneuver. The gastroepiploic vein is divided at the point where it empties
into the gastro colic trunk. The superior mesenteric vein is followed
upwards to the inferior margin of the pancreas. The peritoneum overlying
the lower border of the pancreas is divided to allow better definition of the
pancreatic margins. Two stay sutures are taken at the inferior border of the
pancreas to facilitate the formation of the tunnel in between the pancreatic
neck and the superior mesenteric vein-portal vein trunk. Moving now to
the supraduodenal compartment, Cholecystectomy is done  in a fundus-
first approach. Cystic duct is traced to its origin from the common bile
duct, and the common bile duct is transected just cephalad to this point.
Due care is taken at this point to avoid any iatrogenic injury to the right
hepatic artery, which usually runs behind the hepatic duct[41].  The  distal
end of the common bile duct and its surrounding fibro fatty tissues are
dissected free off the rest of the hepatoduodenal ligament and retracted
caudally. A small noncrushing clamp is applied to the proximal stump of
bile duct preventing any further bile spillage for the rest of the operation.
The proper hepatic artery is identified and looped and is traced proximally
to its origin from  the common hepatic artery. The gastroduodenal artery is
delineated during this dissection. Nodal bearing tissues around the proper
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hepatic artery and the common hepatic artery are excised. The
gastroduodenal artery is divided near its origin. A potential danger here is
the misidentification of a replaced common hepatic artery or even a
replaced right hepatic artery as the gastroduodenal artery. One method to
avoid this mistake is to place  a vascular clamp across the presumed
gastroduodenal artery and checking for pulsations at the porta hepatis prior
to dividing  this vessel. The stomach is then divided and retracted towards
the left upper quadrant of the abdomen. The supra-pancreatic portion of the
portal vein is now widely exposed. Two stay sutures are now placed on the
superior border of the pancreas. These sutures at the superior and inferior
pancreatic borders also serve to ligate the superior and inferior pancreatic
vessels running longitudinally in the parenchyma and reduce bleeding
from the cut edges after transaction. Using peanut swabs and blunt forceps,
a tunnel is created cautiously between the superior mesenteric vein-portal
vein trunks posteriorly and the pancreatic neck anteriorly. A silicon drain
is introduced into this tunnel to loop up the neck. The venous trunk is
examined for any tumour involvement on its posterolateral aspect. If
venous resection is required, this is kept as the last step in the resectional
phase. The portal vein is gently retracted medially exposeing the
underlying tissues, and dividing any venous branches.Simultaneously,the
specimen is retracted to the right. The tissue and branch arteries arising
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from the superior mesenteric artery are serially clamped, divided, and
stitch ligated. During this step, the specimen is cupped within the left hand
of the surgeon, and the fingers continuously keep track of the position of
superior mesenteric artery to avoid any injuries to it. The anterolateral side
of the superior mesenteric artery is completely skeletonised of its investing
tissues. The third part of the duodenum is transected using a linear stapler,
freeing the entire specimen. Margins are taken from the proximal
pancreatic stump and the bile duct for frozen section analysis. The
ligament of Treitz is mobilized. Mesenteric branches to the fourth part of
the duodenum are divided allowing it to be delivered into the
inframesocolic compartment under the superior mesenteric artery. The
pancreatic stump is rotated to the left, and a collar of investing tissue
cleared for about 2 cm from the divided end to provide a clear all-round
visualization of the pancreatic capsule; this facilitates subsequent
comfortable construction of the pancreaticoenteric anastomosis.
Hemostasis is achieved and the operative field is irrigated with warm
saline before proceeding to the reconstructive part  of the operation.
VASCULAR RESECTION
Fuhrman and co-workers (1996) found that tumours adherent to the
superior mesenteric vein – portal vein trunk did not exhibit more
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aggressive biology, suggesting that venous adherence was a function of
tumour location rather than an indicator of aggressiveness. Subsequent
studies have reported that the need for portal vein resection does not affect
overall patient survival. In 2004, new evidence emerged to suggest that
portal vein resection might confer some survival benefits. In a prospective
randomized study, Lygidakis and associates (2004) 29 showed that patients
with portal-mesenteric venous invasion who were randomized to venous
resection had far better 2-year and 5-year survivals compared with patients
who were randomized to only palliative bypass. Venous involvement can
be described as short segment or long segment. As with all vascular
surgery, proximal and distal control must be secured first. For short
segment involvement, a cuff resection is done. The strategy would be to
dissect circumferentially around the point of involvement to allow side
clamping of the vein. The involved area is excised with a longitudinal
bielliptical incision with clear margins, and the venotomy subsequently is
closed in a transverse fashion using nonabsorbable monofilament sutures
in a continuous fashion (Prolene 5-0). If a segmental resection is necessary
to ensure clear margins, reconstruction of the portal vein and superior
mesenteric vein can be accomplished in most instances by an end-to-end
anastomosis. Otherwise, a generous Cattell-Brascsh maneuver with or
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without a caudal mobilization of the liver, usually allows a tension-free
anastomosis.If still not possible , a vein graft can be used.
LYMPHADENECTOMY:
 Several studies exist about extended lymph node dissection and its
possible  benefits. Three level I studies were  reported from centers from
three different continents – Europe 42, North America (United States) 43,44,
30 and Asia (Japan)45. They unanimously said  that the increased radicality
of lymphadenectomy did not prolong survival rates. Ishikawa and
colleagues (1997) provided a possible explanation for these disappointing
results. They found that patients with lymph node metastases confined to
the anterior and posterior panceraticoduodenal groups fared as well as
patients without any lymph node involvement. In contrast, patients with
involvement of other, more distant lymph node groups did not benefit from
an extended lymphadenectomy (Ishikawa et al, 1997). A standard
lymphadenectomy, which would include the removal of the anterior and
posterior pancreaticoduodenal groups, would be adequate .
MANAGEMENT OF PANCREATIC REMNANT:
The aftermath of a pancreatic leak can be devastating, particularly
when it results in retroperitoneal sepsis. This is found to be a major cause
of mortality in whipples procedure [46]. Mere occlusion of the duct has
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been shown to result in higher fistula rates, along with increasing the risk
of pancreatic exocrine and endocrine insufficiency. Drainage of the
pancreatic remnant to the gastrointestinal tract is an important step, but it
runs the risk of anastomotic breakdown. The pancreaticoenteric
anastomosis has grabbed the attention of  surgeons, causing a search for a
more reliable technique to avoid this dreaded complication of anastomotic
leak . Several techniques have been described, and the literature will
continue to report novel techniques promising to be even safer. Rather than
the choice of anastomotic technique, however, the successful management
of the pancreatic anastomosis depends more on the surgeon’s meticulous
execution of the technique with which he or she is familiar 47.
As long as the basic rules of a safe anastomosis are followed,
including careful handling of the pancreatic tissues, a tension-free
approximation, ensuring good blood supply, and no distal obstruction, any
pancreaticoenteric anastomotic technique can have a good outcome. One
of the most commonly employed technique is a pancreaticojejunal
anastomosis. This anastomosis is done by invaginating the transected
pancreas into the end of the jejunum, also known as dunking method ;
another variation is to anastomose the pancreatic duct directly to an
opening in the jejunum, called the duct-to-mucosa technique. The
technique of pancreaticojejunal anastomosis, whether end-to-side or end-
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to-end, and whether duct-to -mucosa or dunking, does not appear to
influence the anastomotic leak rate significantly. Another technique is to
anastomose the pancreatic stump to the stomach. Proponents of the
pancreaticogastrostomy cite various reasons 48. First, it is easier to perform,
because of the close proximity of the stomach to the pancreas. Second, rich
gastric blood supply makes this  anastomosis less prone to ischemia. Third,
because the exocrine enzymes encounter an acidic environment, the leak
rate is theoretically lower as the enzymes do not get activated. The last
statement has been disproved, however. In a prospective randomized trial
comparing pancreaticojejunostomy with pancreaticogastrostomy, the leak
rates were not significantly different  [pancreaticojejunostomy 11%;
pancreaticogastrostomy 12%)49.In a prospective randomized trial 50 of
pancreaticogastrostomy versus pancreaticojejunostomy after
pancreaticoduodenectomy .Yeo et al has concluded that pancreatic fistula
is a common complication after pancreaticoduodenectomy, with an
incidence most strongly associated with surgical volume and underlying
disease and the data do not support the hypothesis that
pancreaticogastrostomy is safer than pancreaticojejunuostomy or is
associated with a lower incidence of pancreatic fistula. In a meta analysis
by  Wente  MN  and  Shrikande  SV  et  al  ,they  concluded  that  all  non
randomized observational clinical studies have reported superiority of
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pancreaticogastrostomy over pancreaticojejunostomy but all randomized
controlled studies has shown equally good results. In a study by H Ramesh
et al results suggested that pancreaticogastrostomy deserves wider
application 52. In another prospective randomized trial Bassi et al has
showed that both type of anastamosis does not influence significantly the
risk of overall complications or the incidence of pancreatic fistula.
However, significant decreases in the risk of associated complications,
biliary fistulas, postoperative collections and DGE were observed using
pancreaticogastrostomy. A Chinese meta analysis of all four randomized
controlled trials has evidence suggesting that  pancreaticogastrostomy is
better than pancreaticojejunostomy after pancreaticoduodenectomy.
Isolated loop Pancreaticojejunostomy:
An ideal reconstructive technique should not only minimize the risk
of Pancreatic fistula formation, but should also ensure that, should a
pancreatic fistula  form, its complications are prevented or minimized. An
isolated jejunal loop for Pancreaticoenteric anastomosis is theoretically
expected to achieve these desired endpoints.  Previous studies, using an
isolated jejunal loop for pancreatoenteric anastomosis can minimize the
risk of Pancreatic Fistula, although its effect in terms of reducing
pancreatic fistula related morbidity is not clear.53–59
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Advocates of this technique believe that diverting bile away from
the pancreaticojejunostomy site minimizes the pancreatic enzyme
activation and hence reduces the risk of pancreato enteric anastomotic
fistula 60 .Another argument cited in favour of using a Roux loop in
Pancreaticojejunostomy relies on the belief that, if a pancreato enteric
anastomotic fistula forms, it will be a ‘pure’ pancreatic fistula and these
fistulae cause lesser complications compared with complex PF, in which
the bile activates the pancreatic juice, with further repercussions.
The isolated Roux loop pancreaticojejunal end-to-side anastomosis
was initially described by Funovics et al. 61 who described 48 patients with
double Roux loops to separate the pancreatic and hepatic anastomoses,
which resulted in a pancreatic fistula rate of 18.6% but a mortality of only
2%. Sutton CD et al in 2004 reported a series of 61 patients with zero
postoperative pancreaticoenteric leaks and mortality rate of 5%.
62/17.However, recent studies have not borne out this promise of better
results .In a recent randomised controlled trial, El Nakeeb et al analysed 90
patients randomly assigned to isolated Roux loop pancreaticojejunostomy
with those of pancreaticogastrostomy after pancreaticoduodonectomy.They
concluded that Isolated loop Pancreaticojejunal anastomosis  was not
associated with a lower rate of post operative pancreatic fistula , but was
associated with a decrease in the incidence of postoperative steatorrhea and
34
the technique allowed for early oral feeding and the maintenance of oral
feeding even if post operative pancreatic fistula developed.63
Operative details of isolated Roux loop pancreaticojejunal anastomosis:
A 40-cm long isolated loop of jejunum is fashioned and passed in
the retrocolic plane through the mesocolon for pancreaticojejunal
anastomosis .
Isolated Loop PJ Single loop PJ
The anastomosis is done by a duct to mucosa technique or a dunking
technique  using 3.0/4.0 prolene  interrupted sutures for the anastomosis.
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BILIARY-ENTERIC ANASTOMOSIS:
In contrast to the pnacreaticoenteric anastomosis, there are fewer
variations to the technique employed for the biliary-enteric anastomosis.
This anastomosis usually is constructed in an end-to-side manner  with a
single interrupted layer of  monofilament absorbable sutures (PDS 5-0)
with C1 needle.
The anastomosis is positioned at about 20 to 30 cm downstream
from the pancreaticojejunostomy in case of a pancreaticogastrostomy or a
single loop PJ.
RECONSTITUTION OF GI CONTINUITY:
Based  on whether a distal gastrectomy or a PPPD was performed,
the reconstruction is done by a gastrojejunostomy (distal gastrectomy) or a
duodenojejunostomy (PPPD).
Abdominal Drains and Nasogastric Tube.
Intraperitoneal drains have been placed near the biliary and
pancreatic anastomosis intending to control leakage of blood or biliary,
lymphatic, or pancreatic secretions. This practice has been prophylactic in
nature, and it is based more on habit rather than evidence. This practice has
been challenged more recently. A randomized trial addressing the value of
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drains after pancreatic resection found that placement of drains did not
translate into a reduction in surgical morbidity 64. Rather, a significantly
higher proportion of patients randomized to the drain group development
intraperitoneal sepsis, fluid collection, or fistula.
RESULTS
After resection of periampullary and pancreatic cancer, longterm
survival is determined largely by the site of origin of tumour. In an
evaluation 242 patients with resected periampullary adenocarcinoma at the
Johns Hopkins Hospital, the 5-year actual survival rate for the entire cohort
was 20%55. Actual 5-year survival rates were the best for duodenal
adenocarcinoma (59%) compared with the rest: ampullary (39%), distal
bile duct (27%) and pancreas (15%). For the entire group of patients
surviving 5 or more years, there were statistically more duodenal and
ampullary primaries, fewer node-positive resections, 35 fewer margin-
positive resections, and more well differentiated tumours compared with
patients who failed to survive 5 years.
In an analysis  of  616 patients  with resected adenocarcinoma of the
pancreas at the Johns Hopkins Hospital, several factors were found to
influence long-term survival shows that lymph node involvement, margin
positivity; tumour size greater than or equal to 3 cm, and poor  tumour
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differentiation all resulted in worse survival. Although there is some
controversy over whether patients do worse with pancreatic
adenocarcinoma arising from the left side versus the right side of the
gland, for patients who undergo resection, there seems to be no statistical
difference in survival. By multivariate analyses, pathologic factors
identified as prognostically favorably affecting outcome were, negative
resection margin, tumour diameter less than 3 cm, and good to moderate
tumour differentiation. Particularly for pancreatic primaries, an important
observation is that the survival rate continues to decline after 5 years,
mostly owing to recurrent disease; 5-year survival does not indicate a cure
of pancreatic cancer, although the decrement in survival beyond 5 years is
less  steep  than  the  decrement  in  survival  from  the  time  of  surgery  to  5
years postoperatively.
ADJUVANT THERAPY : POSTOPERATIVE
CHEMORADIATION AND CHEMOTHERAPY
Overall, the 5-year survival for all patients diagnosed with
pancreatic cancer is only 3%. After resection, approximately15% to 20%
of patients can be expected to survive 5 years, with most dying as a result
of recurrent disease, manifesting locoregionally and distantly.These
patterns of disease recurrence and general poor outcome support the
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rationale for adjuvant chemoradiation. The first randomized controlled trial
evaluating adjuvant therapy for pancreatic cancer was reported by the
Gastrointestinal Tumour Study Group (GITSG). A survival benefit was
seen in patients  randomly assigned to radiation therapy combined with 5-
fluorouracil  (5-FU)  compared  with  surgery  alone  (median  survival  20
months versus 11 months). Despite limited accrual, the GITSG trial was
the first to show a potential benefit for adjuvant therapy after the first to
show a potential benefit for adjuvant therapy after resection of pancreatic
cancer. Subsequent reports from the GITSG and single institutions
supported the use of adjuvant chemoradiation. A randomized controlled
trial done by the European Organization for Research and Treatment of
Cancer showed a trend toward improved survival with adjuvant 5-FU-
based chemo radiation compared with surgery alone in patients with
periampullary and pancreatic cancer (Klinkenbijl et al, 1999); however,
this study was statistically underpowered and reported as a negative
trial.The results from the European Study Group for Pancreatic Cancer
(ESPAC-1) trial were reported by Neoptolemos and colleagues (2004).
Compared with the observation group, however, patients who received
chemoradiation alone seemed to have a worse median survival, suggesting
a possible role for treatment-related toxic radiation effects. Although
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controversy surrounds the use of adjuvant chemoradiation, several on-
going clinical trials are exploring various regimens.
NEOADJUVANT THERAPY
In theory, there are several potential advantages of therapy
administered in the neoadjuvant (preoperative) versus the post operative
adjuvant setting. In a series of 132 patients with resectable pancreatic
cancer at the M.D. Anderson Cancer Center, the investigators reported that
various neoadjuvant chemoradiation regimens followed by
pancreaticoduo- denectomy can be completed successfully with a median
survival of 21 months. Currently, there is no proven survival benefit of
neoadjuvant chemoradiation compared with postoperative therapy;
however, numerous trials are ongoing.
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MATERIALS AND METHODS
All patients admitted with a diagnosis of periampullary carcinoma or
carcinoma head of pancreas, between August 2011 to February 2014 were
evaluated by imaging studies and those patients found to have resectable
disease were selected for study.
All data were collected prospectively and the clinical parameters
were noted in a proforma. Details noted included age, gender, chief
complaints, co-morbid illness, nature of diet, habit of smoking and alcohol
consumption were also noted. Findings on physical examination such as
jaundice, pallor, pedal edema and other signs of liver failure if present
were  noted.  Clinical  examination  of  the  abdomen was  done  to  look  for  a
palpable gallbladder, hepatomegaly and free fluid. A per rectal
examination to rule out any possibility of rectal deposits. Basic
biochemical and hematologic investigations including a complete blood
count, Renal function tests and Liver function tests were noted.
Coagulation profile and serum tumour marker study was done for all
patients. After an initial ultrasonogram of abdomen, an upper GI
endoscopy and contrast enhanced computerised tomography was done for
all patients.
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A total of 128 patients with operable growth in the pancreatic head,
ampullary, distal bileduct and duodenum in the periampullary region were
included in the study group. Informed consent was obtained from all the
patients explaining the nature of illness and the magnitude of morbidity
and mortality. Whenever possible if a growth is seen at endoscopy or side
viewing endoscopy, a biopsy was attempted. MRI was not done routinely,
but if already available at admission and the information needed to assess
the resectability is sufficient, a CECT abdomen was not requested .The
performance status of the patient is assessed and the cardiorespiratory
status evaluated. Hydration status, nutritional status and coagulation profile
are noted and corrected if necessary with injection vitamin K and fresh
frozen plasma. All patients were encouraged to have incentive spirometry
for 2 weeks before surgery. For patients with bilirubin more than 15 mg% ,
poor performance status, and poor nutritional status and for those
presenting with cholangitis a preoperative endoscopic biliary drainage was
performed except for one patient for whom we have performed an
operative biliodigestive bypass before pancreaticoduodenectomy. All
patients in the study were subjected for a standard whipple’s
pancreaticoduodenectomy. With the patient in supine position abdomen is
opened by a rooftop incision and thorough laparotomy done. After
ascertaining the operability once more resection is proceeded.
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Reconstruction pancreaticoenteric anastamosis was done either in the form
of a pancreaticogastrostomy , pancreaticojejunostomy or isolated loop
pancreaticojejunostomy as per the choice of operating surgeon.
Pancreaticogastrostomy is done usually by the
invaginating(dunking) technique in two layers. Pancreaticojejunostomy is
done as an end to side anastomosis by Buchler’s technique. Isolated  loop
pancreaticojejunostomy is done by fashioning an isolated jejuna loop, 40
cm long ,taken in a retrocolic plane. Anastomosis was end to side either
duct to mucosa or dunking method . .Hepaticojejunostomy was done using
3-0 vicryl interrupted sutures by parachute technique. An antecolic
gastrojejunostomy is done in either of the three. The duration of surgery,
blood loss, number of transfusions, the technique of pancreaticoenteric,
bilioenteric and gastrojejunal anastomosis were noted.
The day of removal of nasogastric tube, drainage tube and urinary
catheter in the post-operative period were noted. The values of serum
amylase and drainage tube amylase were noted on the 3rd and if necessary
on the 5th postoperative day. A complete blood count and Liver function
tests were obtained at the time of discharge. The length of postoperative
stay was noted along with major complications like delayed gastric
emptying, early and late haemorrhage, pancreatic leak, intra-abdominal
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collection and other minor complications like wound infection,
pneumonitis and urinary tract infection. The complications after whipple’s
operation as noted in the proforma were defined as follows:
Delayed Gastric Emptying
All patients who were unable to start oral fluids by 7th day and those
who required ryles tube for more than 10 days or who required reinsertion
after 10 days were considered to have delayed gastric emptying.
Haemorrhage
Bleeding complication following pancreaticoduodenectomy
requiring monitoring, transfusion, radiological and surgical intervention
were noted. Early haemorrhage occur within 24 hrs and late haemorrhage
occurred after 24 hrs.
Pancreatic leak
Any measurable amount of fluid after day 3 in the drainage tube
with amylase level more than 3 times that of serum values is suggestive of
pancreatic leak and has been graded A,B & C according to the severity and
plan of management.
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Intra-abdominal collection
Any collection detected by ultrasonogram or CECT of more than 5
cm is noted as intra abdominal collection and planned for percutaneous
drainage.
Wound infection
Any collection of pus or fluid at the operated site with mild fever,
leucocytosis and local inflammatory signs in the absence of any major
complications is defined as wound infection. It was managed by letting out
the pus or fluid, sending it for culture and sensitivity treating with
appropriate antibiotics.
Pneumonitis
Any post-operative lung signs with fever and diminished air entry is
defined as basal pneumonitis and aggressively treated by ambulation,chest
physiotherapy, antibiotics and nasal oxygen.
Urinary Tract Infection
Patients presented with fever with no other sources and positive
urinary culture. Treated by hydration, antibiotics and adequate glycemic
control.
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STATISTICAL ANALYSIS
The data collected in the proforma were entered in an excel sheet of
Microsoft Office software and inference obtained after statistical analysis.
The mean and standard deviation were reported for continuous variables
and for categorical variables proportions were computed. To compare and
find the statistical significance between the two group proportions chi-
square test was used and to compare between the two group means
independent t-test was used. The P-values <0.05 were considered to
indicate statistical significance.
CECT ABDOMEN SHOWING PERIAMPULLARY LESION
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CHOLESTATIC LIVER WITH DISTENDED GALLBLADDER
KOCHERISATION
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GASTRODUODENAL ARTERY LIGATION
PANCREATIC REMNANT
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PANCREATICOGASTROSTOMY SEEN THROUGH
ANTERIOR GASTROTOMY
AFTER COMPLETION OF PANCREATICOGASTROSTOMY
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HEPATICOJEJUNOSTOMY
GASTROJEJUNOSTOMY
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PANCREATIC STUMP MOBILISED
ROUX LOOP FASHIONED
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DUCT TO MUCOSA PJ ISOLATED LOOP
RESECTED SPECIMEN
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RESULTS
Among the one hundred and thirty eight patients included in the
study 62% were male and 38% were female patients. The minimum age
was  30  and  maximum  age  was  72  with  a  mean  age  of  51.7  .On  clinical
presentation 90% had jaundice, 86% had abdominal pain, 84% had weight
loss, 56% had pruritus, 11% had fever, 12% had cholangitis and 28% had
other symptoms such as nausea, vomiting, loss of appetite and
constipation.
SYMPTOMATOLOGY
Symptoms Frequency Percentage
Jaundice 124 90
Abdominal pain 118 86
Weight loss 115 84
Pruritus 77 56
Cholangitis 15 11
Fever 16 12
Others 38 28
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On evaluating the patients for co-morbid illness 24% had Diabetes
Mellitus, 10% had hypertension 2% had bronchial asthma and 22% had
previous surgery.
CO-MORBID ILLNESS & PREVIOUS SURGERY
Co-morbidity Frequency Percentage
Diabetes mellitus 28 20.2
Hypertension 26 18.8
COPD 15 10.86
Previous surgery 28 20.28
CLINICAL EXAMINATION
Findings Frequency Percentage
Icterus 112 81.15
Pallor 38 27.53
Palpable gallbladder 98 71.01
Hepatomegally 56 40.57
On examination, 81.15% were icteric and 27.53% had pallor.
Gallbladder was palpable in 71.01% of patients and liver was palpable in
40.57% of patients. Liver echoes were found to be normal in 92% of
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patients. Intrahepatic biliary radical dilatation was found in 96% and
Common bileduct was dilated in 92% of the patients.
ULTRASONOGRAM FINDINGS
Parameters Frequency Percent
Liver echoes 127 92.02
IHBR Dilatation 136 96.37
CBD dilatation 128 92.75
Mass visualised 56 40.57
Ultrasonogram was able to diagnose the mass only in 40.57% of the
patients. Vascular involvement  of the portal vein alone was pre-
operatively diagnosed in  one patients  who underwent resection. MRI scan
was done in 32 % of patients. Biopsy was available  in 65% of patients and
pre-operative biliary drainage was done in 19.56% of patients.
PREOPERATIVE BIOPSY AND BILIARY DRAINAGE
Procedure Frequency Percent
BIOPSY DONE 91 65.94
PREOP BILIARY
DRAINAGE
27 19.56
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Among the study population the distribution of disease were as
follows: periampullary 102[79.68%], pancreatic 15[11.7%], distal CBD
6[6%] and duodenal growth 5[4.6%].
Among the one hundred and thirty eight  patients, patients with one
morbidity condition were 14%, with two conditions were 12%, with three
conditions were 14% and 60% had no morbidity. Among the
complications delayed gastric emptying occurred in 57[44.53%],
haemorrhage in 7[5.4%], pancreatic leak in 30.46%( grade A-20 [15.6%],
grade B-12 [9.3%], and grade C-7[5.4%]), intraabdominal collection in
15%, wound infection in 22%, pneumonitis in 7%, urinary tract infection
in 6% of patients. At the time of discharge about 84% had a normal blood
count and 78 % had a normal liver function tests.
N=138 Minimum Maximum Mean
Standard
deviation
Age 27 72 50.74 11.242
Hb 8.5 14.8 9.6 2.162
TC 4200 18000 8721.40 3362.493
P 42 92 71.62 9.710
L 10 43 26.92 8.342
E 0 11 4.84 2.339
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ESR 11 165 64.20 31.768
TB 0 39 17.73 8.321
DB 0 22 12.34 5.832
SAP 75 770 310.72 181.230
Albumin 2.3 5.0 2.253 .4976
PT 11 22 12.46 2.132
INR 0.9 1.74 1.1322 0.1772
CA.19-9 8 244.9 51.314 41.712
DURN_SURG 180 660 310 111.56
BLOOD LOSS 80 4500 400 634.91
TRANSFUSION 2 8 2.90 1.465
RT_REMOVAL 2 45 5.63 2.328
URINARY 2 12 5.47 2.774
DT REMOVAL 2 20 8.63 5.016
SERUM
AMYLASE
0 790 89.90 87.813
DT AMYLASE 0 7239 265.5 1281.30
57
INTRAOPERATIVE VARIABLES (PG Vs PJ Vs ISOL PJ)
Technique N Mean Standarddeviation P value
Duration of
surgery
PG 39 240 minutes 35
0.562PJ 61 270 minutes 25
ISOL PJ 38 320 minutes 45
Blood loss
PG 39 550 ml 125
0.562PJ 61 625ml 75
ISOL PJ 38 610ml 100
Transfusion
PG 39 2.14 units 0.56
0.056PJ 61 2.35 units 0.75
ISOL PJ 38 3.45 units 1.09
POSTOPERATIVE EVENTS (PG Vs PJ Vs Isol PJ)
Technique N Mean
Standard
deviation
P value
RT_Removal
PG 39 7.5 2.1 0.45
PJ 61 7.77 7.2
PJ ISOL 38 8.2 8.5
Urinary
PG 39 6.25 0.5 0.75
PJ 61 6.73 1.03
PJ ISOL 28 6.66 1.5
DT_removal
PG 39 9.33 2.2 0.052
PJ 61 9.92 3.0
PJ ISOL 38 11.52 2.5
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Serum
amylase
PG 39 68.58 22.4 0.65
PJ 61 50.50 12.2
PJ ISOL 28 76.23 34.8
DT amylase
PG 39 418.54 34.34 0.78
PJ 61 151.69 22.9
PJ ISOL 38 224.35 45.2
Post_stay
PG 39 12.58 2.3 0.81
PJ 61 13.08 3.5
PJ ISOL 38 15.34 4.5
When comparing between the three groups undergoing
pancreaticogastrostomy , pancreaticojejunostomy  and isolated loop
pancreaticojejunostomy ,the incidence of delayed gastric emptying in the
PG group was 38.46% , the incidence in the PJ group was 40.98% and in
the isolated loop pancreaticojejunostomy group was 44.73%.The incidence
of haemorrhage was 7.6% in the PG group, 6.5% in the PJ group and nil in
the isolated PJ group . When comparing the incidence of leak between the
three groups it was about 33% in the PG and 29.5% in the PJ group and
15.78%  in isolated PJ group. The incidence of intra abdominal collection
in the PG group was 7[17.9%], in the PJ group it was7[ 11.4%] and in the
isolated PJ group was 5 [13.15%]. Regarding the incidence of minor
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morbidities, the incidence of wound infection was 20.8% in the PG and
26.9% in the PJ group and 22% in isolated PJ group. The incidence of
pneumonitis in the PG group was 2 [5.1%] compared to 4[6.5%] in the PJ
group and 3[7.8%] in Isolated PJ group. The incidence of urinary tract
infection in the PG group was 1[2.5%] and in the PJ group it was
2[3.2%].and 1 [2.6%] in  isolated  PJ  group. The mean duration of
nasogastric tube removal was 7.5 days in the PG group and 7.8 days in the
PJ group and 7.0 in Isolated PJ group. The mean days of urinary catheter
removal was 6.3 days in the PG and 6.7 in the PJ  group and 8.0 in isolated
PJ group. The mean days of drainage tube removal was 9.3 days in the PG
and 9.9 days in the PJ group and 11 in the isolated loop PJ group. The
mean postoperative hospital stay was 12.6 days in the PG group and 13.1
days in the PJ group and 11.2 in isolated PJ group
The mortality in the patients who underwent pancreaticogastrostomy
was 5.1% ,in the pancreaticojejunostomy group was 4.9 %and  7.8 %in
isolated loop PJ .The overall mortality rate was 5.79%.
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MORTALITY (PG Vs PJ Vs Isolated Loop PJ]
Technique Total No Mortality
Percentage
Mortality
PG 39 2 5.1
PJ 61 3 4.9
ISOL LOOP 38 3 7.8
Overall Mortality 5.79
P value 1.04
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DISCUSSION
Though the concept of cure after pancreaticoduodenectomy has been
challenged, surgical resection is the only therapy for malignancies of the
head of pancreas and periampullary region, which gives the patient a
significantly increased survival. The mortality ranges between 3-5% and
the morbidity following pancreaticoduodenectomy is still in the range of
40-60%. Morbidity and mortality arising out of such a major surgical
intervention requires special attention for those with limited survival (10-
30% are true 5 year survivors). Hence analyzing the peri-operative factors
influencing the morbidity and mortality is important for improving
outcome following this demanding surgical procedure. In our study we
have evaluated the perioperative variables which influence the outcome
between isolated loop pancreaticojejunostomy, single loop
pancreaticojejunostomy and pancreaticogastrostomy . We have also tried
to analyse whether isolated  loop pancreaticojejunostomy gives better
results compared to the other two anastomosis .We also tried to find out if
there was any difference in outcome between duct to mucosa and dunking
type anastomosis in each of the three types of anastomosis .
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Age & sex
As per various studies the peak incidence of pancreatic cancer is in
the 60’s and 70’s and the mean age at diagnosis is 60-65 years11. There is a
slightly higher incidence in men than in women (relative risk 1.35) and
advancing age is perhaps the stronger risk factor. In our study the
minimum age  at  diagnosis  was  30  and  the  maximum age  was  at  72.  The
mean age of presentation was 51.74 with a standard deviation of 10.9.
Out of the 128 patients (61.71%) were male and 19(38.29%) were
female patients.
Clinical presentation
The hallmark of presentation for periampullary and pancreatic
cancer is jaundice, resulting from obstruction of the intrapancreatic portion
of the common bile duct1 . Although some patients exhibit a vague
abdominal pain, locally advanced pancreatic cancer with tumour invasion
of celiac plexus typically causes a constant dull pain accompanied by back
pain. on-specific symptoms such as nausea, anorexia, weight loss and
fatigue are common in many patients. Weight loss of 10% or more is well
known to affect outcome adversely with an overall increased susceptibility
to postoperative complications. In our study 90% of patients presented
with jaundice and 86% presented with abdominal pain. 84% presented
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with weight loss, 56% presented with pruritus, 12% with fever and 14%
with cholangitis. Other symptoms like nausea, vomiting, loss of appetite
and fatigue were present in 28% of patients. Patients with cholangitis and
poor performance status were subjected to endoscopic biliary drainage. All
the 15 patients with cholangitis were managed initially by endoscopic
biliary drainage. One of the patient who presented with cholangitis with
performance status ECOG 3 as we were are not possible to drain either
endoscopically or percutaneously we offered an operative biliodigestive
bypass and resected subsequently. A total of 27 patients had preoperative
biliary drainage .
Nutritional status and co-morbid illness
Lillemoe et al observed that 15-20% patients with pancreatic cancer
had new-onset diabetes mellitus11 .  As many patients are elderly33 there is
also a higher incidence of co-morbid illness. Cardio-pulmonary testing
assess the ability to deliver oxygen during stress and the need for
postoperative ventilator support. Weight loss and dehydration are frequent
features in such patients and hence need to be aggressively addressed. In
our study diabetes mellitus was the major co-morbid illness with an
incidence of 24%, hypertension 10%, bronchial asthma 2% and 21.8% had
previous surgery particularly in the female population.
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Out  of  the  8  patients  with  mortality   6   of  the  patients  had
hypertension and 6  patients had diabetes mellitus.. All patients with
previous surgery were females and 15 out of the 28 patients had undergone
puerperal sterilisation. Previous surgery did not have any impact in the
duration of surgery when compared with patients who had no previous
operation.
Personal habits
Though dietary habits have no direct influence, they have indirect
influence in the form of nutritional status and hence the performance
status. 60% of patients were non-vegetarians and 40% were vegetarians.
This dietary habit had no influence on the outcome. The study had
32% smokers and 48% with history of alcohol intake . Patients who were
found to be nutritionally depleted were encouraged to take adequate enteral
nutrition  and albumin infusion was administered preoperatively. Patients
with significant pulmonary co morbidity were all smokers. A period of
abstinence from  smoking for at least 2 weeks before surgery, incentive
spirometry, lung function tests, nebulisation with bronchodilators and
mucolytics, aggressive postoperative chest physiotherapy and ventilator
support formed part of the management protocol for these patients .
Among the patients with mortality three  were smokers.
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Physical examination
Jaundice was the most common clinical presentation with 82% and
20% were anaemic. Gall bladder was palpable in 78% of the patients and
liver was palpable in 40%.
Imaging, endoscopy and biopsy
All patients underwent initial ultrasonogram of the abdomen and
pelvis.
Liver was found to have normal echoes in 91.4% of patients with
intrahepatic biliary radical dilatation in 97.6% of study group. Common
bile duct dilatation was diagnosed in 96.8% of patients, whereas mass in
the head of pancreas or periampullary region was diagnosed only in
34.37% of patients. Therefore the accuracy of ultrasonogram in detecting
IHBR dilatation is more than that of CBD dilatation which in turn is more
than the presence of mass. Hence ultrasonogram is an easily available, cost
effective, less time consuming and adequate initial imaging study to
differentiate between proximal and distal biliary obstruction but the
disadvantage is the observer variation which is operator dependent. There
is considerable evidence in literature that helical CT is the most efficacious
initial imaging study16 and is the most sensitive initial tool to diagnose and
stage pancreatic cancer17.Our  practice  is  to  do  a  64  slice  MDCT   with
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pancreatic protocol with vascular reconstruction for all patients to assess
the resectablity with accuracy18. Those patients deemed to be unresectable
by distant metastasis, peritoneal metastasis and vascular invasion were not
included in the study except for one patient with solid and cystic
components of head of pancreas with portal vein involvement for which
we have done a pancreaticoduodenectomy and vascular resection with
grafting.Upper GI endoscopy for all patients and attempted for a biopsy if
feasible with a side viewing scopy. If clinical, biochemical and imaging
modalities suggest distal obstruction and operable growth we proceed with
surgery even if the biopsy turns out to be negative or inconclusive after
explaining to the patient and the relatives of the possibility of a benign
postoperative biopsy report. Out of the 138 patients 91patients were
biopsied preoperatively  and all the preoperative  biopsies correlated with
postoperative biopsy reports. Among these , 89 were periampullary
carcinomas where biopsy was done by side viewing endoscopy and 2 were
carcinoma head of pancreas , where CT guided FNAC was done .
Preoperative biliary drainage
There are 6 prospective randomized studies(Hattfield et al 1982,Mc
person et al 1984, Smith et al 1985, Smith et al, Lai et al, Wig et al) which
analysed the outcome after a preoperative biliary drainage.
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Only 2 studies suggested that preoperative biliary drainage is
beneficial (Smith et al & Wig et al). A meta-analysis by Sewnath has
showed that routine preoperative biliary drainage carries no benefit38.
Instead there is a high complication rate with prolonged hospital stay.
Saleh and his associates have showed that there is no evidence of either a
beneficial or an adverse effect of preoperative biliary stenting. We have
done preoperative biliary drainage for 27 patients(19.56%). Majority of the
indications were for cholangitis and the rest for poor performance status or
with biliribin more than 15. Our current protocol is to opt for preoperative
biliary drainage in patients with bilirubin more than 15 mg %.One patient
underwent open surgical biliodigestive bypass for poor nutritional status
with vomiting with ECOG3 and later proceeded with resection.
Provisional diagnosis
The distribution of diseases in our study as follows:
Periampullary102 (79.68%), head of pancreas 15(11.7%), duodenal
5 (4.6%) and distal bileduct 6(6%).
Biochemical parameters
The mean haemoglobin concentration was 9.8 with lowest at 8.7 and
highest at 14.2 and the need for preoperative transfusion is decided when
haemoglobin is less than 8g%.The mean total count was 6361.4 and the
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highest was 18000 which is a clue to diagnose cholangitis earlier and
hence decide upon urgent endoscopic biliary decompression. The mean
bilirubin value is 15.8mg% as literature evidence suggests malignancy
with a level above 10mg%. The mean serum alkaline  phosphatase value
was 304.8. Serum albumin was from 2.2 – 5.4 and the average value is
3.25g%.
Intraoperative factors
The mean duration of surgery was 296.79 minutes [4.94hours ]with
shortest duration of 4 hours and longest duration of 11 hours. This patient
had a portal vein resection with venous graft. The mean blood loss was
646.52 ml and on an average blood requirement was 2.79 units per patient.
Type of anastomosis
Among the 138 patients 39 underwent pancreaticogastrostomy, 61
underwent pancreaticojejunostomy single loop and 38 underwent isolated
loop pancreaticojejunostomy . On analyzing the preoperative variables
among both the sub-groups they were almost comparable, with minor
difference they were not statistically significant. There are 4 randomized
controlled trials, 1favouring pancreaticogastrotomy in terms of lesser leak
rate (Fernandezcruz L et al,2008). 3 RCT’s (Bassi et al, Yeo et al & Duffas
et al) have showed PG and PJ to be similar in terms of leak rate. 1 A meta-
analysis by Mc Kay et al has favoured PG and another meta-analysis by
69
Wente et al has shown no difference between both subgroups in terms of
leak as well as major morbidity.
Operative time
Anastomosis No Time
P value
PJ Isol  Vs
PG
Pj Isol Vs
PJPG 39 240 minutes
PJ 61 270 minutes 0.045 0.052
ISOL PJ 38 320 minutes
Mean operative time was 4hours in the PG group,4.5 hours in PJ
group and  5.3 hours in isolated loop PJ group. On average , isolated loop
anastomosis took  50 minutes longer than a single loop PJ and 80 minutes
longer than a PG anastomosis .
 The amount of estimated blood loss in PG group was 550 ml ,in the
PJ group was 625 ml and 610 ml in isolate loop PJ group. Comparing
between the three subgroups there was no significant difference in terms of
removal of nasogastric tube, drainage tube and postoperative stay.
Biochemical investigation reports at the time of discharge showed no
significant difference between the three subgroups.
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The incidence of haemorrhage was 7.6% (3) in the PG and 6.5% [4]
in the PJ group .There were no hemorrhagic complications in the isolated
PJ group. Four  patients were managed by endoscopically and two patients
were managed conservatively. One patient died following profuse bleeding
from PG site despite endoscopic therapy .
The incidence of pancreatic leak was 33 % in the PG group
compared to 29.5% the PJ group and 15.78 %.This shows a  significant
decrease with isolated loop anastomosis . There is also an improving trend
as initially , we preferred PG anastomosis  followed by PJ and then a move
to Isolated loop PJ and raises the possibility of a learning curve effect .
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The incidence of intra-abdominal collection was 25.64% in the PG
group compared to 23.52 % in the PJ group and 21.05 % in the isolated PJ
group.
The incidence of wound infection in the PG group was 25.64%  and
in the PJ group it was 26.4% and 21.05% in the Isolated loop PJ group .
5.8% patient developed pneumonitis in the isolated PJ group , but PG
group had 5.1% and  the PJ group had 4.7%.Urinary tract infection was
seen in  5.1% in the PG group, 4.9 % in PJ group and none in the isolated
loop PJ group.
DELAYED GASTRIC EMPTYING (PG Vs PJ Vs ISOL LOOP)
Delayed gastric emptying
A B C Total [%]
P value
ISOL PJ
VS PG
ISOL PJ
VS PG
PG 7 3 5 15[38.46]
0.052 0.045
PJ 15 6 4 25[40.98]
Isolated
loop
10 4 3 17[44.73]
All[%] 32[25] 13[10.15] 12[9.3] 57[44.53]
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DGE Isolated loop
Anastomosis
Total
number
A B C Total%
Duct to
mucosa
22 5 3 2 10[45.45]
Dunking 16 5 1 1 7[43.75]
Total 38 10[26.31] 4[10.52] 3[7.8] 17[44.73]
P value 0.75
Haemorrhage
Total Early Late Luminal Extra
luminal
False
extra
luminal
Sentinel
bleed
Mild Severe
PG 3 2 1 1 2 0 1 2 1
PJ 4 2 2 4 0 0 4
Isolated
loop
0 0 0 0 0 0 0 0
All 7[5.4%] 6[4.6%] 1[0.7%] 1[0.7%] 4[3.1%] 1[0.7%] 1[0.7%] 6[85.71%] 1[14.28%]
Anastomotic leak
A B C No leak
Total
Leak %
Total
P Value
PG Vs
ISOL
PJ Vs
ISOL
PG 6 5 2 26 33 39
0.67 0.75
PJ 10 5 3 43 29.5 61
Isolated loop 4 2 2 32 15.78 38
Total 20 12 7 30.46
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Isolated loop
Total No
38
A  B  C
No
leak
Total leak
%
P value
PG Vs ISOL PJ VS ISOL
Duct to
mucosa
22 2 0 0 20 9.09
1.02 1.24
Dunking 16 2 2 2 10 37.5
Morbidity 49[39.28%]
Leak DGE
Haemorrhage Wound
infection
Intra
abdominal
collection
UTI Pneumonitis
PG 13[33.33%] 15[38.4%] 3[7.6%] 10[25.64%] 10[25.64%] 2[5.1%] 2[5.1%]
PJ 18[29.5%] 25[40.9%] 4[6.5] 16[26.4%] 14[23.52%] 3[4.91%] 2[3.27%]
ISOL 8[21.05%] 17[44.7% 0 8[21.05%] 6[15.78%] 0 3[7.8%]
Total 39[30.46%] 57[44.53] 7[5.4%] 19[14.84%] 18[14.06%] 5[3.9%] 7[5.4%]
Total 159
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Among the 138 patients 57 patients developed delayed gastric
emptying, 36 patients developed DGE and pancreatic leak and 17 patients
developed other complications along with DGE and pancreatic leak
accounting for a morbidity of 39.28%. The incidence of delayed gastric
emptying in the PG group was38.46[15],in the  PJ group which was
40.98%[25] and in the isolated limb PJ group was 44.73%[17]. The
maximum days we have retained the nasogastric tube was for 26 days. We
have managed the patients with prokinetics and maintaining them on
enteral feeding through feeding jejunostomy. Pancreatic leak  occurred in
39 patients with grade A leak in 20(15.62%), grade B leak in 12(9.37%)
and grade C leak in 7(5.46%) patients. All patients with pancreatic leak
were managed by non-operative means. Grade A leaks  were managed
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conservatively and grade B leaks required supportive care in the
postoperative ward with drainage tube retained for a prolonged period and
grade  C  leaks  were  managed  aggressively  in  the  ICU  with  one  or  more
image guided percutaneous drainage tubes and nutritional support. We
have not reoperated for a suspected leak.
Intra abdominal collection
Anastomosis Total number Intra abdominal
collection
PG 39 10[25.64%]
PJ 61 7[11.47%]
Isol Loop PJ 38 6[15.78%]
Total 23[16.6%]
P =0.67 not significant
Pneumonitis
Anastomosis Total number Pneumonitis
PG 39 2[5.1%]
PJ 61 2[3.27%]
Isol Loop PJ 38 3[7.8%]
Total 7[5.4%]
P= 0.564
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Wound Infection
Anastomosis Total number Wound infection
PG 39 10[25.64%]
PJ 61 7[11.47%]
Isol Loop PJ 38 8[21.05%]
Total 19[14.84%]
UTI
Anastomosis Total number UTI
PG 39 2[5.1%]
PJ 61 3[4.91%]
Isol Loop PJ 38 0
Total 5[3.9%]
P=0.768
Mortality
Mortality [%] Duct to mucosa Dunking
PG 2[5.1] 1 1
PJ 3[4.9] 2 0
Isolated loop 3[7.8] 1 1
Total 8[5.7]
P=1.078
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The mortality rate in our study was 5.7% (5.1% in PG group and
4.9% in PJ group, 7.8% in isolated loop PJ group). The mortality rate in
the literature is in the range of 3-5%. In our study the reason for mortality
were due to cardirespiratory impairment due to myocardial infarction and
other two cases were due to haemorrhage and metabolic encephalopathy.
One of the patient had an urgent endoscopy and we could not find any
bleeding points except for clots. Patient was on ventilator with
haemodynamic support and could not be shifted for angioembolisation. We
reopened and explored but could not find the source and patient
succumbed with  multiorgan failure. The other patient was
haemodynamically unstable on day 4 and before we could intervene
patient succumbed due to metabolic encephalopathy. Both the patients had
adequately controllable co-morbid illnesses. Though our study showed a
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33.3% leak in the PG group and 29.5% in the PJ and 21.05%leak rate in
the isolated loop PJ group, the incidence of type C leak was 6.4% in th PG
group , 4.91% in PJ group and 5.1 % in the isolated loop PJ group .Two of
these in the isolated limb PJ group died of multiorgan failure and sepsis
.Both of these did not have pancreatic anastomotic leak .One in the PG
group succumbed to hemorrhagic complications .
Mortality :Duct to mucosa Vs Dunking
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In summary, there is no significant difference in mortality rate
between the three types of anastomosis, though the incidence of higher
grade fistulae and fistula related mortality was lower with isolated loop
.Incidence of delayed gastric emptying is higher and hospital stay longer
with isolated loop anastomosis.
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CONCLUSION
 In comparison to pancreatico gastrostomy or single loop
pancreatico jejunostomy, Isolated loop pancreatico jejunal anastomoses
might lead to lower incidence of higher grade of pancreatic leak in both
soft and in normal pancreas.
Both dunking and duct to mucosa type anastomoses seem to have
similar incidence of leaks , in all three type of anastomosis .
There is no significant difference in mortality rate between the three
types of pancreaticoenteric anastomosis .However , incidence of higher
grade leak and anastomotic leak related mortality is lower with isolated
loop  anastomosis
Incidence of delayed gastric emptying seems to be higher and
hemorrhagic complications rarer with isolated loop pancreaticojejunal
anastomosis  compared to other types of pancreaticoenteric anastomosis.
So , isolated loop pancreatic stump anastomosis seems to be less
prone to anastomotic leak though there is higher incidence of delayed
gastric emptying and prolonged hospital stay.
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DATA SHEET
Analysis of results of Isolated loop pancreatic stump anastomosis following Whipples
procedure
Name : Age /Sex: Ip.No :
DOA: DOS: DOD:
Diagnosis:
Complaints : Abdominal pain :
Jaundice :
Fever :
Pruritus:
Weight loss:
Cholangitis :Y/N
Others :
H/O past illness: DM/HT/CHD/BR.Asth /TB/
      Previous Surgery
Personal history : Smoker /Alchohol /Veg /Nonveg
Physical examination: Icterus /pallor
       P/A Palpable gallbladder /liver /free fluid
       P/R exam
Preoperative investigations :
CBC Hb TC DC ESR
LFT TB DB SAP Albumin
PT INR
92
Ca 19.9
USG liver texture
IHBR
CBD
Mass  head of pancreas /periampullary
OGD:
SVS:
CECT abdomen
MRI:
Preoperative biliary drainage : Yes /No
Biosy ;Yes /No
Provisional diagnosis : Ampullary
Duodenal
Distal CBD
Head of pancreas
Duration
Blood loss
Technique D2M Dunking
PJ
ISOL  PJ
PG
Bile duct :
93
GJ tupe : Antecolic /retrocolic
Blood transfusion
Post op course :
RT removed on
Urinary cath removed on
DT removed on
Post op Biochem investigations
DT amylase
Serum amylase
CBC
LFT
Post operative stay  ____days
Morbidity :
Major : DGE
Anastomotic leak
Hemorrhage
Intra abdominal collection
Minor: wound infection
Pneumonitis
UTI
Mortality :
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INFORMATION TO PARTICIPANTS
Title:  - “Study of results of isolated loop pancreaticojejunal anastomosis
following whipples procedure”
Principal Investigator:  Dr.T.S.Chandrasekar
Co-Investigator(if any):
Name of Participant:
Site :
You are invited to take part in this research/ study/procedures/tests. The
information in this document is meant to help you decide whether or not to take
part. Please feel free to ask if you have any queries or concerns.
What is the purpose of research?
We have obtained permission from the Institutional Ethics Committee.
The study design
 Prospective and Retrospective study
Study Procedures
The study involves evaluation of results following isolated loop
pancreaticojejunal anastomosis following whipples procedure . The planned
scheduled involve visits at _____,_____,____,  and______(days/ weeks) after
your initial visit. You will be required to visit the hospital _______ number of
times during the study.
At each visit, the study physician will examine you. Some [blood / urine
/imaging/clinical examination other] tests will be carried out at each visit. [… …
ml of blood will be collected at each visit. Blood collection involves prick with a
needle and syringe.] These tests are essential to monitor your condition, and to
assess the safety and efficacy of the treatment given to you.
In addition, if you notice any physical or mental change(s), you must contact the
persons listed at the end of the document.
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You may have to come to the hospital (study site) for examination and
investigations apart from your scheduled visits, if required.
Possible risks to you – If any, Briefly mention
Possible benefits to you - If any, Briefly mention
Possible benefits to other people
The results of the research may provide benefits to the society in terms of
advancement of medical knowledge and/or therapeutic benefit to future patients.
Confidentiality of the information obtained from you
You have the right to confidentiality regarding the privacy of your medical
information (personal details, results of physical examinations, investigations,
and your medical history). By signing this document, you will be allowing the
research team investigators, other study personnel, sponsors, Institutional Ethics
Committee and any person or agency required by law like the Drug Controller
General of India to view your data, if required.
The information from this study, if published in scientific journals or presented
at scientific meetings, will not reveal your identity.
How will your decision to not participate in the study affect you?
Your decision not to participate in this research study will not affect your
medical care or your relationship with the investigator or the institution. You
will be taken care of and you will not loose any benefits to which you are
entitled.
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Can you decide to stop participating in the study once you start?
The participation in this research is purely voluntary and you have the right to
withdraw from this study at any time during the course of the study without
giving any reasons. However, it is advisable that you talk to the research team
prior to stopping the treatment/discontinuing of procedures etc.
Signature of Investigator Signature of Participant
Date                                                                                 Date
N
a
m
e
A
g
e
s
e
x
D
I
A
G
N
O
S
I
S
A
n
a
s
t
D
T
M
/
D
u
n
k
i
n
g
A
b
d
_
p
a
i
n
J
a
u
n
d
i
c
e
F
e
v
e
r
P
r
u
r
i
t
u
s
W
t
_
l
o
s
s
C
h
o
l
a
n
g
i
t
i
s
O
t
h
e
r
s
D
M
H
T
B
A
P
r
e
_
s
u
r
g
e
r
y
N
.
V
V
e
g
S
m
o
k
e
r
A
l
c
I
c
t
e
r
u
s
P
a
l
l
o
r
G
B
L
i
v
e
r
H
b
T
C P L E
E
S
R
T
B
D
B
S
A
P
A
l
b
P
T
I
N
R
C
A
1
9
-
9
L
i
v
e
r
_
E
c
h
o
I
H
B
R
C
B
D
M
a
s
s
Rajakannu 45 M PERIAMPULLARY CA PG 1 1 1 2 1 1 2 1 2 2 2 2 1 2 2 1 1 2 1 2 7.5 4600 70 15 5 68 3 2 243 2.9 11 0.91 13.8 1 1 1 2
rajendran 42 M PERIAMPULLARY CA PJ 1 1 1 2 1 1 2 1 2 2 2 2 1 2 1 1 1 2 1 2 9 4800 80 12 6 26 16 8 436 3.6 14 1.16 120 1 1 1 1
singaram 62 M PERIAMPULLARY CA PJ 1 1 1 2 2 2 2 2 1 2 2 2 1 2 1 1 1 2 1 2 10 5600 63 20 4 45 12 10 384 3.6 12 1 58 1 1 1 2
Subramani 58 M PERIAMPULLARY CA PJ 2 1 1 1 1 1 1 2 2 2 2 2 1 2 2 1 1 2 1 1 8.6 14000 60 38 2 126 20.6 12.8 684 2.9 18 1.5 104 2 1 1 2
Deivasigamani 68 M PERIAMPULLARY CA PJ 2 1 2 2 2 1 2 2 1 1 2 2 1 2 1 1 2 2 2 2 10.2 6800 67 28 4 29 1.8 0.9 112 3.9 12 1 26 1 2 2 2
Vijaya 45 F PERIAMPULLARY CA PJ 2 1 1 2 2 1 2 2 2 2 2 1 1 2 2 2 1 1 1 1 8.8 7600 64 30 6 54 14.6 7.4 256 3.6 13 1.08 82 1 1 1 2
Salomi 35 F PERIAMPULLARY CA PJ 1 1 1 2 2 1 2 2 2 2 2 1 1 2 2 2 1 2 1 2 7.9 4300 73 24 3 77 16.2 6.9 186 3 12 1 18 1 1 1 2
Malar 30 F CA HOP PJ 1 1 1 1 1 1 1 1 2 2 2 2 1 2 2 2 1 2 1 1 8 18000 64 23 9 120 24.9 20.8 540 2.2 18 1.5 112 1 1 1 2
Parvathi 72 F PERIAMPULLARY CA PJ 1 1 1 2 1 1 2 2 1 2 2 1 2 1 2 2 1 2 2 2 7 3400 70 28 2 33 12 8 120 3 12 1 20 1 1 2 2
Kaleshasherif 47 M PERIAMPULLARY CA PJ 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 12 4500 58 36 5 40 3 1.2 80 3.2 14 1.16 26 1 1 2 2
Yanathi 60 M PERIAMPULLARY CA PJ 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 1 2 1 1 9.4 5400 60 34 6 46 16 12 420 3.8 12 1 21 1 1 1 2
Renganayaki 50 F PERIAMPULLARY CA PJ 2 1 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 2 13.8 3600 64 30 1 50 18 14 680 3.6 13 1.08 38 2 1 1 1
Kumar 66 M PERIAMPULLARY CA PJ 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 10.2 4800 66 34 4 80 14 12 720 2.8 14 1.16 22 1 1 1 2
Karunanidhi 54 M PERIAMPULLARY CA PJ 2 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1 1
Chokkalingam 72 M PERIAMPULLARY CA PJ 2 1 1 1 1 1 1 2 1 1 2 2 1 2 1 1 1 2 1 1 12 12200 86 12 2 146 21 14.6 490 3 16 1.33 94 1 1 1 2
Chinnapillai 60 M PERIAMPULLARY CA PJ 2 2 1 2 1 1 2 1 1 1 2 2 1 2 1 2 1 2 1 2 11 8700 67 31 4 56 16 12 324 3 14 1.16 22 1 1 1 2
Kesavan 40 M PERIAMPULLARY CA PJ 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 9 880 58 32 8 50 19 16 200 3 12 1 30 1 1 1 2
Maragatham 60 F PERIAMPULLARY CA PJ 1 1 1 2 1 1 2 2 2 2 2 1 2 1 2 2 1 1 1 2 7 4400 86 16 2 80 19 14 120 3.4 13 1.08 32 1 1 1 2
Krishnan 40 M PERIAMPULLARY CA PJ 1 2 1 2 1 1 2 2 2 2 2 2 1 2 1 1 1 2 1 2 9 4300 76 22 4 45 19 14 256 2.8 14.6 1.2 33 1 1 1 2
Elumalai 69 M PERIAMPULLARY CA PJ 1 1 1 1 1 1 1 2 1 2 2 2 1 2 1 1 1 1 1 1 7 3450 62 24 8 125 23.5 19 446 2.9 16 1.33 32 1 1 1 2
Maragatham 51 F CA HOP PG 2 1 2 2 2 1 2 1 2 2 2 1 1 2 2 2 2 2 2 2 9.6 5800 72 22 4 45 0.33 0.11 452 4.1 10.09 0.8 32 1 1 1 1
Sathyanarayana 57 M PERIAMPULLARY CA PJ 2 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 9 880 58 32 8 50 19 16 200 3 12 1 30 1 1 1 2
Babu 67 M PERIAMPULLARY CA PG 2 2 1 2 1 2 2 2 1 2 2 2 2 1 1 1 1 2 1 1 9.2 9400 82 12 3 45 20.6 17.2 316 3.6 15.7 1.3 62 1 1 1 2
Narasimman 60 M PERIAMPULLARY CA PG 1 2 1 2 1 1 2 2 2 2 2 2 2 1 1 1 1 2 1 1 9.8 3900 45 33 2 40 7.5 4.5 458 2.7 14.1 1.16 235.9 1 1 1 1
Rajammal 70 F PERIAMPULLARY CA PG 2 1 2 2 2 1 2 1 2 2 2 2 2 1 2 2 2 1 2 2 9.2 4800 48 42 6 72 0.7 0.3 72 3.2 13.1 1.11 20 1 1 1 1
Dhanabackiam 45 F PERIAMPULLARY CA PG 1 1 2 1 1 2 2 2 2 2 1 1 2 2 2 1 2 1 2 12 9.7 78 21 2 66 17 13 196 3.4 12 1 22 1 1 1 2
Samikannu 55 M PERIAMPULLARY CA PG 1 1 1 2 2 2 2 1 2 2 2 2 1 2 2 2 1 2 1 2 8.6 9200 76 21 3 60 2.9 1.7 256 2.8 14.6 1.2 30 1 1 1 1
Gunalan 65 M PERIAMPULLARY CA PG 1 2 1 2 1 1 2 2 1 2 2 2 1 2 2 2 1 2 1 2 9.6 5600 80 18 2 98 18 12 322 3 12 1 80 1 1 1 1
Premkumari 50 M CA HOP PG 2 1 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 2 10.5 6500 73 23 9 67 15.5 11.8 105 3.6 15 1.25 67.74 1 1 1 2
Nawab jan 68 M PERIAMPULLARY CA PG 2 1 2 1 2 1 1 2 2 1 1 2 2 1 2 1 1 1 2 1 2 10.2 7600 67 32 5 20 22 16.4 670 3 18 1.5 98 1 1 2
Ravi 48 M PERIAMPULLARY CA PG 2 1 1 2 1 1 2 2 2 2 2 2 1 2 1 1 1 2 1 2 13 4600 76 30 4 60 16 14.4 340 3.4 12 1 32 1 1 1 2
Thilagam 40 F PERIAMPULLARY CA PG 2 1 2 2 2 1 2 1 2 2 2 1 1 2 2 2 2 2 2 2 9.6 5800 72 22 4 45 0.33 0.11 452 4.1 10.09 0.8 32 1 1 1 1
Shankaran 40 M PERIAMPULLARY CA PJ 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 9 880 58 32 8 50 19 16 200 3 12 1 30 1 1 1 2
Pujiammal 40 F PERIAMPULLARY CA PG 1 1 1 2 1 2 1 2 2 2 2 1 2 1 2 2 1 2 2 1 4.7 8300 75 19 3 24 21.9 13.8 293 3.2 11 1.02 26 2 1 1 1
Aravalli 40 F PERIAMPULLARY CA PG 1 1 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 2 10.5 6500 73 23 9 67 15.5 11.8 105 3.6 15 1.25 67.74 1 1 1 2
Vasantha 47 F PERIAMPULLARY CA PG 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 2 1 2 1 2 12 4500 76 22 4 34 17.8 12.4 120 3.2 12 1 20 1 1 1 2
sulochana 60 F PERIAMPULLARY CA PJ 2 1 1 2 1 1 2 2 1 1 2 1 2 1 2 2 1 1 1 1 6.6 5600 70 22 8 55 19.8 11 420 2.9 15 1.25 26 1 1 1 2
Fathima beevi 46 F PERIAMPULLARY CA PG 2 1 1 2 1 1 2 2 1 2 2 1 2 1 2 2 1 1 1 1 8 2300 68 33 6 102 18 10 336 2.6 19.6 1.64 112 1 1 1 2
Dhanabackiam 56 F PERIAMPULLARY CA PG 2 1 1 2 1 1 2 2 1 2 2 2 1 2 2 2 1 2 1 2 11 6800 72 23 7 23 22 11 234 3 15 1.25 34 1 1 1 1
Sekar 47 M PERIAMPULLARY CA PJ 2 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 1 12.8 7300 68 21 7 106 18 16 212 3 12 1 20 1 1 1 2
Viswanathan 45 M PERIAMPULLARY CA PJ 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 9 880 58 32 8 50 19 16 200 3 12 1 30 1 1 1 2
Natarajan 40 M PERIAMPULLARY CA PJ 1 1 1 2 1 1 2 2 2 2 2 2 1 2 2 1 2 1 2 1 10.2 4500 66 24 6 12 20 17.9 302 3.4 12 1 100.4 1 1 1 2
Gopal 58 M PERIAMPULLARY CA PG 1 1 1 2 1 1 2 2 2 2 2 2 1 2 1 1 1 2 1 2 13 4600 76 30 4 60 16 14.4 340 3.4 12 1 32 1 1 1 2
MASTER CHART
Subramani 58 M PERIAMPULLARY CA PG 2 1 1 2 2 1 2 2 2 2 2 2 2 1 1 1 1 2 1 1 12 4500 80 17 3 50 15.6 11.5 102 3 15 1.25 24 1 1 1 2
Sagadevan 45 M PERIAMPULLARY CA PG 2 2 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 1 9.4 10600 76 34 7 156 26.8 20.9 159 5.4 13 0.9 90 1 1 1 1
Krishnan 40 M PERIAMPULLARY CA PG 2 1 2 2 2 1 2 2 2 2 2 2 2 1 1 1 2 2 2 1 9.9 11600 73 17 10 40 1.2 0.6 96 3.3 15.9 1.22 50.4 2 1 1 1
Balasubramanian 57 M PERIAMPULLARY CA PG 1 1 1 1 1 1 1 1 2 2 1 2 1 2 2 2 1 2 1 2 12 10200 62 38 4 112 29 18 441 3.9 11.2 0.89 30.2 1 1 1 1
selvam 46 M PERIAMPULLARY CA PJ 1 1 1 2 1 1 2 2 2 2 2 2 1 2 2 1 1 2 1 1 8.3 12200 90 7 3 10 23 16 122 3.3 12 1 64 1 1 2 1
Saradha 50 F PERIAMPULLARY CA PG 2 1 1 1 1 1 1 1 2 2 2 2 1 2 2 2 1 2 1 1 14.2 10600 78 18 4 15 22 18 680 3.1 11.6 0.92 20 1 1 1 1
suseela 47 F carcinoma head of pancreasPG 1 1 1 2 2 1 2 1 2 2 2 1 1 2 1 1 1 2 1 1 6.5 7400 81 8 1 64 18.5 11 139 2.9 17.4 1.45 32 1 1 1 1
AARAVALLI 40 F PERIAMPULLARY CA PG 2 2 1 2 1 2 2 2 2 2 2 2 1 2 2 2 1 1 1 2 10.5 6500 75 33 4 14 15.5 11.8 105 3.6 17 1.2 67.74 1 1 1 1
RANIAMMAL 65 F PERIAMPULLARY CA PG 2 1 1 2 1 1 2 2 2 2 2 2 1 2 1 1 1 2 1 2 13 4600 76 30 4 60 16 14.4 340 3.4 12 1 32 1 1 1 2
DHANABAKIAM 50 F PERIAMPULLARY CA PG 1 1 1 2 2 1 2 2 2 2 2 2 2 1 1 1 1 2 1 1 12 4500 80 17 3 50 15.6 11.5 102 3 15 1.25 24 1 1 1 2
BALASUBRAMANIAM 57 M CA HOP PG 2 1 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 1 9.4 10600 76 34 7 156 26.8 20.9 159 5.4 13 0.9 90 1 1 1 1
Subramani 67 M PERIAMPULLARY CA PG 2 1 1 2 2 1 2 2 2 2 2 2 2 1 1 1 1 2 1 1 12 4500 80 17 3 50 15.6 11.5 102 3 15 1.25 24 1 1 1 2
Sagadevan 45 M PERIAMPULLARY CA PG 2 2 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 1 9.4 10600 76 34 7 156 26.8 20.9 159 5.4 13 0.9 90 1 1 1 1
Krishnan 44 M PERIAMPULLARY CA PG 2 1 2 2 2 1 2 2 2 2 2 2 2 1 1 1 2 2 2 1 9.9 11600 73 17 10 40 1.2 0.6 96 3.3 15.9 1.22 50.4 2 1 1 1
Balasubramanian 57 M PERIAMPULLARY CA PG 1 1 1 1 1 1 1 1 2 2 1 2 1 2 2 2 1 2 1 2 12 10200 62 38 4 112 29 18 441 3.9 11.2 0.89 30.2 1 1 1 1
selvam 46 M PERIAMPULLARY CA PJ 1 1 1 2 1 1 2 2 2 2 2 2 1 2 2 1 1 2 1 1 8.3 12200 90 7 3 10 23 16 122 3.3 12 1 64 1 1 2 1
Saradha 55 F PERIAMPULLARY CA PG 2 1 1 1 1 1 1 1 2 2 2 2 1 2 2 2 1 2 1 1 14.2 10600 78 18 4 15 22 18 680 3.1 11.6 0.92 20 1 1 1 1
suseela 47 F CA HOP PG 1 1 1 2 2 1 2 1 2 2 2 1 1 2 1 1 1 2 1 1 6.5 7400 81 8 1 64 18.5 11 139 2.9 17.4 1.45 32 1 1 1 1
AARAVALLI 44 F PERIAMPULLARY CA PG 2 2 1 2 1 2 2 2 2 2 2 2 1 2 2 2 1 1 1 2 10.5 6500 75 33 4 14 15.5 11.8 105 3.6 17 1.2 67.74 1 1 1 1
RANIAMMAL 65 F PERIAMPULLARY CA PG 2 1 1 2 1 1 2 2 2 2 2 2 1 2 1 1 1 2 1 2 13 4600 76 30 4 60 16 14.4 340 3.4 12 1 32 1 1 1 2
DHANABAKIAM 50 F PERIAMPULLARY CA PG 1 1 1 2 2 1 2 2 2 2 2 2 2 1 1 1 1 2 1 1 12 4500 80 17 3 50 15.6 11.5 102 3 15 1.25 24 1 1 1 2
BALASUBRAMANIAM 57 M PERIAMPULLARY CA PG 2 1 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 1 9.4 10600 76 34 7 156 26.8 20.9 159 5.4 13 0.9 90 1 1 1 1
SELVAM 60 M PERIAMPULLARY CA PG 2 1 2 2 2 1 2 2 2 2 2 2 2 1 1 1 2 2 2 1 9.9 11600 73 17 10 40 1.2 0.6 96 3.3 15.9 1.22 50.4 2 1 1 1
SARADHA 50 F PERIAMPULLARY CA PG 1 1 1 1 1 1 1 1 2 2 1 2 1 2 2 2 1 2 1 2 12 10200 62 38 4 112 29 18 441 3.9 11.2 0.89 30.2 1 1 1 1
SELVAM 46 M PERIAMPULLARY CA PG 1 2 1 2 1 1 2 2 2 2 2 2 1 2 2 1 1 2 1 1 8.3 12200 90 7 3 10 23 16 122 3.3 12 1 64 1 1 2 1
SUSEELA 47 F CA HOP PG 1 2 1 1 1 1 1 1 2 2 2 2 1 2 2 2 1 2 1 1 14.2 10600 78 18 4 15 22 18 680 3.1 11.6 0.92 20 1 1 1 1
PANDURANGAN 60 M PERIAMPULLARY CA PG 1 2 1 2 2 1 2 1 2 2 2 1 1 2 1 1 1 2 1 1 6.5 7400 81 8 1 64 18.5 11 139 2.9 17.4 1.45 32 1 1 1 2
THANGAMARI 47 F PERIAMPULLARY CA PG 2 1 1 2 1 2 2 2 2 2 2 2 1 2 2 2 1 1 1 2 10.5 6500 74 10 5 33 15.5 11.8 105 3.6 11 0.9 67.74 1 1 1 1
SAMUTHIRAM 52 M PERIAMPULLARY CA PG 2 2 1 2 1 2 2 1 1 2 2 2 1 2 1 1 1 1 2 2 10.8 8000 82 18 5 34 0.8 0.2 227 3.4 10.4 0.85 55 1 1 1 2
RAJARAM 65 M PERIAMPULLARY CA PG 2 1 1 2 1 1 2 1 2 2 2 2 1 2 2 1 1 2 1 2 7.5 4600 70 15 5 68 3 2 243 2.9 11 0.91 13.8 1 1 1 2
GANAPATHI 60 M CAHOP PG 2 1 1 2 1 1 2 1 2 2 2 2 1 2 1 1 1 2 1 2 9 4800 80 12 6 26 16 8 436 3.6 14 1.16 120 1 1 1 1
NAGALAKSHMI 45 F PERIAMPULLARY CA PG 2 1 1 2 2 2 2 2 1 2 2 2 1 2 1 1 1 2 1 2 10 5600 63 20 4 45 12 10 384 3.6 12 1 58 1 1 1 2
AARAVALLI 40 F PERIAMPULLARY CA PG 2 1 1 1 1 1 1 2 2 2 2 2 1 2 2 1 1 2 1 1 8.6 14000 60 38 2 126 20.6 12.8 684 2.9 18 1.5 104 2 1 1 2
RANIAMMAL 65 F PERIAMPULLARY CA pj 2 2 2 2 2 1 2 2 1 1 2 2 1 2 1 1 2 2 2 2 10.2 6800 67 28 4 29 1.8 0.9 112 3.9 12 1 26 1 2 2 2
DHANABAKIAM 50 F CA HOP pj 1 2 1 2 2 1 2 2 2 2 2 1 1 2 2 2 1 1 1 1 8.8 7600 64 30 6 54 14.6 7.4 256 3.6 13 1.08 82 1 1 1 2
BALASUBRAMANIAM 57 M PERIAMPULLARY CA pj 1 2 1 2 2 1 2 2 2 2 2 1 1 2 2 2 1 2 1 2 7.9 4300 73 24 3 77 16.2 6.9 186 3 12 1 18 1 1 1 2
SELVAM 60 M PERIAMPULLARY CA pj 1 1 1 1 1 1 1 1 2 2 2 2 1 2 2 2 1 2 1 1 8 18000 64 23 9 120 24.9 20.8 540 2.2 18 1.5 112 1 1 1 2
SARADHA 50 F PERIAMPULLARY CA pj 1 1 1 2 1 1 2 2 1 2 2 1 2 1 2 2 1 2 2 2 7 3400 70 28 2 33 12 8 120 3 12 1 20 1 1 2 2
SELVAM 46 M PERIAMPULLARY CA pj 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 12 4500 58 36 5 40 3 1.2 80 3.2 14 1.16 26 1 1 2 2
SUSEELA 47 F CA HOP pj 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 1 2 1 1 9.4 5400 60 34 6 46 16 12 420 3.8 12 1 21 1 1 1 2
PANDURANGAN 60 M PERIAMPULLARY CA pj 1 2 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 2 13.8 3600 64 30 1 50 18 14 680 3.6 13 1.08 38 2 1 1 1
THANGAMARI 47 F PERIAMPULLARY CA pj 1 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 10.2 4800 66 34 4 80 14 12 720 2.8 14 1.16 22 1 1 1 2
SAMUTHIRAM 52 M PERIAMPULLARY CA PG 2 2 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1 1
RAJARAM 65 M PERIAMPULLARY CA PG 2 2 1 2 1 1 2 1 2 2 2 2 1 2 2 1 1 2 1 2 7.5 4600 70 15 5 68 3 2 243 2.9 11 0.91 13.8 1 1 1 2
GANAPATHI 60 M CAHOP PG 2 2 1 2 1 1 2 1 2 2 2 2 1 2 1 1 1 2 1 2 9 4800 80 12 6 26 16 8 436 3.6 14 1.16 120 1 1 1 1
NAGALAKSHMI 45 F PERIAMPULLARY CA PG 2 1 1 2 2 2 2 2 1 2 2 2 1 2 1 1 1 2 1 2 10 5600 63 20 4 45 12 10 384 3.6 12 1 58 1 1 1 2
AZAGU 60 M CA HOP PG 2 1 1 1 1 1 1 2 2 2 2 2 1 2 2 1 1 2 1 1 8.6 14000 60 38 2 126 20.6 12.8 684 2.9 18 1.5 104 2 1 1 2
JAGADEESH 32 M CA HEAD/UNCI PG 2 1 2 2 2 1 2 2 1 1 2 2 1 2 1 1 2 2 2 2 10.2 6800 67 28 4 29 1.8 0.9 112 3.9 12 1 26 1 2 2 2
ALAGAMMAL 50 F PERIAMPULLARY CA PG 2 1 1 2 2 1 2 2 2 2 2 1 1 2 2 2 1 1 1 1 8.8 7600 64 30 6 54 14.6 7.4 256 3.6 13 1.08 82 1 1 1 2
RAJENDRAN 50 F CA HOP PJ[ISO] 1 1 1 2 2 1 2 2 2 2 2 1 1 2 2 2 1 2 1 2 7.9 4300 73 24 3 77 16.2 6.9 186 3 12 1 18 1 1 1 2
RANGAPPAN 65 M CA HOP PJ[ISO] 1 2 1 1 1 1 1 1 2 2 2 2 1 2 2 2 1 2 1 1 8 18000 64 23 9 120 24.9 20.8 540 2.2 18 1.5 112 1 1 1 2
MEENATCHI 60 F PERIAMPULLARY CA PJ[ISO] 1 2 1 2 1 1 2 2 1 2 2 1 2 1 2 2 1 2 2 2 7 3400 70 28 2 33 12 8 120 3 12 1 20 1 1 2 2
KULANTHAISAMY 55 M PERIAMPULLARY CA PJ[ISO] 1 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 12 4500 58 36 5 40 3 1.2 80 3.2 14 1.16 26 1 1 2 2
AANDI 60 M PERIAMPULLARY CA PJ[ISO] 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 1 2 1 1 9.4 5400 60 34 6 46 16 12 420 3.8 12 1 21 1 1 1 2
RAJAN 37 M PERIAMPULLARY CA PG[D] 2 1 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 2 13.8 3600 64 30 1 50 18 14 680 3.6 13 1.08 38 2 1 1 1
CHOKKAMMAL 54 F PERIAMPULLARY CA PJ[ISO] 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 10.2 4800 66 34 4 80 14 12 720 2.8 14 1.16 22 1 1 1 2
REHMATHUNNISA 37 F CA HOP PJ[ISO] 1 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1 1
JEYARAJ 47 M PERIAMPULLARY CA PJ[ISO] 1 2 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 2 13.8 3600 64 30 1 50 18 14 680 3.6 13 1.08 38 2 1 1 1
BHASKAR 54 M PERIAMPULLARY CA PJ[ISO] 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 10.2 4800 66 34 4 80 14 12 720 2.8 14 1.16 22 1 1 1 2
PARAMASIVAM 40 M CA D2-3 PJ[ISO] 1 2 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1 1
RAMANI 42 M PERIAMPULLARY CA PG[D] 2 2 1 2 1 1 2 2 2 2 2 2 1 2 2 2 1 1 2 2 10 7700 75 23 4 45 19.1 12 246 3 20 1.95 63.2 1 1 1 2
SELVI 60 F PERIAMPULLARY CA PJ[ISO] 1 2 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 2 13.8 3600 64 30 1 50 18 14 680 3.6 13 1.08 38 2 1 1 1
RANJINI 27 F PERIAMPULLARY CA PJ[ISO] 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 10.2 4800 66 34 4 80 14 12 720 2.8 14 1.16 22 1 1 1 2
hariraman 45 m PERIAMPULLARY CA PG[D] 2 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1 1
VEERAPPAN 60 M CA HOP PJ[ISO] 1 1 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 2 13.8 3600 64 30 1 50 18 14 680 3.6 13 1.08 38 2 1 1 1
DILLI 60 M PerIAMPULLARY CA PJ[ISO] 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 10.2 4800 66 34 4 80 14 12 720 2.8 14 1.16 22 1 1 1 2
srinivasan 52 m PERIAMPULLARY CA PJ[ISO] 1 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1 1
Angu 56 M DUODENAL CA PJ[ISO] 1 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1 1
Vittabai 67 F PERIAMPULLARY CA PG[D] 2 2 1 2 2 1 2 1 2 2 2 2 1 2 2 2 1 1 2 2 10.5 9500 77 24 4 45 0.7 13 205 3.5 11.3 0.8 0.6 1 1 1 2
Paulraj 55 M CA HOP PJ[ISO] 1 2 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 2 13.8 3600 64 30 1 50 18 14 680 3.6 13 1.08 38 2 1 1 1
Ramalingam 56 M CA HOP PJ[ISO] 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 10.2 4800 66 34 4 80 14 12 720 2.8 14 1.16 22 1 1 1 2
Anandaraj 44 M PERIAMPULLARY CA PJ[ISO] 1 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1 1
Omana 56 F PERIAMPULLARY CA PJ[ISO] 2 2 2 1 2 2 2 1 1 1 2 2 1 2 2 1 2 2 no 2 9.8 6800 76 26 4 34 4.9 2 128 2.9 17.4 1.26 12 1 1 1 2
Rajeswari 45 F CA HOP PJ[ISO] 1 2 1 2 2 2 2 2 1 2 2 2 1 2 2 2 2 1 1 2 12 6500 78 25 5 44 11 6 243 4 17 1.2 24 1 1 1 1
Feroz khan 40 M PERIAMPULLARY CA PJ[iso] 1 2 1 2 1 1 2 2 2 2 2 2 1 2 2 1 1 1 2 2 14.8 7300 67 17 4 45 19.8 268 4.2 13 0.9 11.2 1 1 1 1
Datchinaamoorthi 56 M PERIAMPULLARY CA PJ[ISO] 1 2 1 2 2 2 2 2 1 2 2 2 1 2 1 2 1 1 2 2 11 4300 75 37 5 43 22 11 223 3.3 14 0.8 45 1 1 1 1
Balu 42 M PERIAMPULLARY CA PJ[ISO] 1 1 2 2 2 1 2 1 1 2 2 2 1 2 1 1 2 1 2 2 9.6 7600 77 33 4 43 0.9 0.2 82 3.5 14 1.3 35.1 1 1 1 1
Savaraiyah 60 M PERIAMPULLARY CA PJ[iso] 1 1 1 2 1 2 2 2 1 2 2 2 1 2 2 1 1 2 1 1 10.3 10000 80 37 5 45 8.8 4 76 3.5 14.7 1.04 290.7 1 1 1 2
Shanmugam 70 M PERIAMPULLARY CA PJ[iso] 1 1 2 2 2 2 2 2 1 1 1 2 2 1 1 1 1 1 2 1 11 11000 75 47 5 42 0.9 0.2 34 2.9 14 1 224 1 2 1 1
Duraisamy 65 M DUODENAL CA PJ[ISO] 1 1 1 2 2 2 2 2 1 1 1 2 2 1 1 1 1 1 1 1 12 5000 77 34 6 47 2.3 1 45 3.2 13 1.2 34 1 2 1 1
Thenmozhi 55 F PERIAMPULLARY CA PG[D2m]1 1 1 1 1 1 1 1 2 1 2 1 1 2 2 2 1 1 2 2 10.2 7700 67 34 5 55 7.1 3 146 2.9 12.8 0.9 4.7 1 1 1 2
Sudhakar 30 M CA HOP PJ[iso] 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 13.2 6500 67 33 4 24 0.5 0.3 500 4.3 15.8 1.17 11.5 1 1 1 2
sowriammal 70 F PERIAMPULLARY CA PJ[ISO] 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 2 11.7 6700 60 37 3 24 1 0.2 267 3.2 12 0.7 47.9 1 1 1 1
chakkubai 55 F duodenal ca PJ[ISO] 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 10 7700 60 37 3 24 0.8 0.1 73 4.1 12 0.9 19.3 1 1 1 1
HALEEMA 45 F DISTAL CBD PJ[ISO] 2 2 1 1 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 11.5 6500 68 34 4 45 3.4 2 230 3.6 611.6 1 2 1 1
KUPPAN 60 M DISTAL CBD PJ[iso] 1 2 1 2 1 1 2 2 2 1 2 2 1 2 2 2 1 1 2 2 10.2 7700 70 26 4 24 1.4 0.8 93 3.3 12.8 0.96 53.1 2 1 1 2
Kalimuthu 65 M DISTAL CBD PJ[ISO] 2 2 1 2 1 1 2 1 1 1 2 2 1 2 2 1 1 1 2 1 10 12800 69 25 6 33 4.4 1.2 454 2.8 15.6 1.03 173.3 2 1 1 2
Rakkammal 55 F PERIAMPULLARY CA PJ[iso] 2 1 1 1 2 1 2 1 2 2 2 2 1 2 2 2 1 1 1 2 7 19400 80 17 13 33 15.5 8.9 606 2.7 15.9 1.15 1.7 2 1 1 1
Balaraman 60 m PERIAMPULLARY CA PJ[ISO] 1 1 2 2 2 2 2 2 2 2 2 2 1 2 1 1 2 1 2 2 10.3 7700 60 37 3 24 8.5 3 73 4.1 12 0.9 1412 1 1 1 1
kalyanasundaram 70 m PERIAMPULLARY CA Pj[isol] 2 1 1 2 1 1 2 2 2 2 2 2 1 2 2 2 1 1 1 2 11 4500 69 8 5 34 12 8 67 3 11 0.9 145 1 1 1 1
Palani 39 m PERIAMPULLARY CA PJ[ISO] 2 2 1 1 1 2 2 2 2 2 2 2 1 2 1 1 1 1 2 2 10 7700 60 37 3 24 10.4 8.4 345 4.1 12 0.9 39 1 1 1 1
PERIASAMY 68 m DISTAL CBD PJ[ISOL]2 1 1 2 1 1 2 2 2 2 2 1 1 2 1 1 1 1 1 2 8.7 6900 43 47 10 38 23.2 16.4 250 2.5 17 1.4 262 1 1 1 1
parvathiammaal 70 F DISTAL CBD PG[DTM]2 2 1 2 1 1 2 2 2 2 2 2 1 2 2 2 1 1 1 1 11 4200 76 37 4 34 22 16 223 3.5 15.6 1.4 244 1 1 1 2
babu 39 M PERIAMPULLARY CARCINOMAPG[DTM]1 2 1 1 1 1 1 2 2 2 2 2 1 2 2 2 1 1 2 2 9.8 3900 73 40 5 45 7.5 4.5 458 2.7 16.4 1.2 19 1 1 1 1
badrunnisa 55 F PERIAMPULLARY PJ 1 2 1 1 1 1 1 2 2 2 2 2 1 2 2 2 1 1 2 2 9.8 3900 73 40 5 45 7.5 4.5 458 2.7 16.4 1.2 19 1 1 1 1
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1 3.5 2 2 2 1 2 2 2 2 10 800 2 PG 7 6 8 84 68 1 1 15 2 2 4 2 1 2 2 2
1 2.6 2 2 2 2 2 1 2 2 5 200 0 PJ 8 10 12 96 54 1 1 16 2 2 4 2 2 2 2 2
1 1 2 2 2 1 1 2 2 2 5 250 0 PJ 12 8 14 120 100 1 1 14 1 2 4 1 1 1 2 2
1 1.5 2 1 1 1 1 2 2 2 4.5 100 0 PJ 9 7 10 120 86 1 1 12 2 2 4 2 1 2 2 2
1 2.6 2 2 2 2 2 1 2 2 5 80 0 PJ 11 8 14 102 450 1 1 18 1 2 2 1 1 2 2 2
1 1.1 2 2 2 1 1 2 2 2 5 120 0 PJ 7 5 10 102 50 1 1 12 2 2 4 2 2 2 2 2
1 1.5 2 1 2 1 1 2 2 2 4 80 0 PJ 7 4 9 86 42 1 1 11 2 2 4 2 2 2 2 2
1 1 2 1 1 1 2 2 2 1 6 200 0 PJ 9 4 8 24 36 1 1 14 2 2 4 2 2 2 2 2
1 3 2 2 2 1 1 2 2 2 6 100 0 PJ 8 7 9 40 80 1 1 10 2 2 4 2 2 2 2 2
1 1 2 2 2 1 2 1 2 2 4 100 0 PJ 8 4 9 30 66 1 1 12 2 2 4 2 2 2 2 2
1 2 2 2 2 1 1 2 2 2 6 120 0 PJ 6 8 9 40 36 1 1 12 2 2 4 2 2 2 2 2
1 3 2 2 2 1 2 2 1 2 6 100 0 PJ 7 6 8 32 74 1 1 14 2 2 4 2 2 2 2 2
1 2.2 2 2 2 2 2 2 2 1 6 200 0 PJ 8 5 9 26 58 1 1 13 2 2 4 2 2 2 2 2
1 3.2 2 2 2 2 1 2 2 2 6 200 0 PJ 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
1 2.2 2 1 2 1 1 2 2 2 8 1050 3 PJ 0 0 0 0 0 0 0 0 2 1 3 1 2 2 2 1
1 2 2 2 2 2 2 1 2 2 7 220 0 PJ 9 12 10 23 46 1 1 18 2 2 4 2 1 1 1 2
1 2 2 2 2 1 1 2 2 2 6 100 0 PJ 6 8 9 34 64 1 1 14 2 2 4 2 2 2 2 2
1 4 2 2 2 2 2 1 2 2 4 100 0 PJ 6 4 9 24 36 1 1 14 2 2 4 2 2 2 2 2
1 1.2 2 2 2 1 1 2 2 2 5 200 0 PJ 8 9 20 45 680 1 1 20 2 2 2 1 1 2 2 2
1 2 2 1 1 1 1 2 2 2 6 560 0 PJ 8 7 10 34 58 1 1 12 2 2 4 2 1 2 2 2
1 2 2 2 2 1 1 2 2 2 4 150 0 PG 11 9 14 45 160 1 1 16 1 2 1 2 2 2 2 2
1 2 2 2 2 1 2 1 2 2 6 100 0 PJ 6 8 9 34 64 1 1 14 2 2 4 2 2 2 2 2
1 2 2 2 2 1 1 2 2 2 4 200 0 PG 10 9 15 86 46 1 1 16 1 2 1 2 2 2 2 2
1 2.6 2 2 2 2 2 1 2 2 6 200 2 PG 8 7 6 6 10 2 1 13 2 2 4 2 1 2 2 2
1 4 2 2 2 1 2 1 2 2 6 100 0 PG 5 4 9 48 24 1 1 11 2 2 4 2 2 2 2 2
1 3 2 2 2 1 2 1 2 2 4 150 0 PG 5 4 8 35 80 1 1 12 2 2 4 2 2 2 2 2
1 3 2 1 1 2 1 2 2 2 3.5 800 1 PG 7 6 8 620 410 2 1 10 2 2 4 2 2 2 2 2
1 2 2 2 2 1 1 2 2 2 6 200 0 PG 6 8 9 45 85 1 1 12 2 2 4 2 1 2 1 2
1 3 2 2 2 1 1 2 2 2 6 200 0 PG 8 7 9 60 45 1 1 10 2 2 4 2 2 2 2 2
1 3 2 1 1 1 2 1 2 2 7 800 2 PG 9 6 11 50 102 1 1 15 2 2 4 2 1 2 1 2
1 4 2 2 2 1 2 2 1 2 6 200 0 PG 7 6 9 42 50 1 1 14 2 2 4 2 2 2 2 2
1 2 2 2 2 1 1 2 2 2 4 150 0 PG 11 9 14 45 160 1 1 16 1 2 4 2 2 2 2 2
1 2 2 2 2 1 2 1 2 2 6 100 0 PJ 6 8 9 34 64 1 1 14 2 2 4 2 2 2 2 2
1 1.3 2 2 2 1 1 2 2 2 4 400 0 PG 6 7 9 123 35 1 1 11 2 2 4 2 2 2 2 2
1 3 2 2 2 1 1 2 2 2 6 200 0 PG 8 7 9 60 45 1 1 10 2 2 4 2 2 2 2 2
1 1 2 2 2 1 1 2 2 2 6 150 0 PG 8 6 9 45 46 1 1 12 2 2 4 2 2 2 2 2
1 1 2 2 2 1 1 2 2 2 7 560 4 PJ 0 0 0 0 0 0 0 0 0 1 3 1 2 1 2 1
1 1.2 2 1 2 1 1 2 2 2 8 450 3 PG 0 0 0 0 0 0 0 0 0 1 3 1 2 2 2 1
1 2.8 2 1 1 1 1 2 2 2 7 550 4 PG 0 0 0 0 0 0 0 0 0 1 3 1 2 2 2 1
1 2.8 2 2 2 1 1 2 2 2 8 900 3 PJ 14 12 16 102 800 2 1 18 1 2 2 2 1 2 2 2
1 2 2 2 2 1 1 2 2 2 6 100 0 PJ 6 8 9 34 64 1 1 14 2 2 2 2 2 2 2 2
1 3.4 2 1 2 1 1 2 2 2 8 800 4 PJ 15 12 18 66 560 2 1 20 1 2 2 1 2 2 1 2
1 4 2 2 2 1 1 2 2 2 6 200 0 PG 7 6 9 42 50 1 1 14 2 2 1 2 2 2 2 2
1 1.5 2 2 2 1 1 2 2 2 5 150 0 PG 8 5 10 58 69 1 1 12 2 2 4 2 2 2 2 2
1 2.8 2 1 2 1 1 2 2 2 7 1100 2 PG 16 6 8 55 170 1 1 17 1 2 1 2 2 2 2 2
1 8 1 2 2 1 2 1 2 2 11 4650 7 PG 12 10 16 13 8297 2 2 20 1 2 3 1 2 2 2 2
1 2 2 1 1 1 1 2 2 2 9 300 2 PG 6 10 11 32 24 1 1 15 2 2 2 2 2 2 2 2
1 2 2 2 1 1 1 2 2 2 5 300 0 PJ 9 6 8 45 349 1 1 12 2 2 1 2 2 2 2 2
1 1.3 2 2 1 1 2 2 1 2 5 600 0 PG 6 4 12 28 21 1 1 16 2 2 2 2 1 2 2 2
1 2.5 2 2 1 1 2 2 2 1 4 400 2 7 4 6 56 45 1 1 23 2 2 1 2 1 1 1 2
1 2.5 2 2 2 2 1 2 2 2 6 200 2 PG 8 3 9 23 34 1 1 45 2 2 2 2 2 2 2 2
1 4 2 2 2 1 1 2 2 2 6 200 0 PG 7 6 9 42 50 1 1 14 2 2 1 2 2 2 2 2
1 1.5 2 2 2 1 1 2 2 2 5 150 0 PG 8 5 10 58 69 1 1 12 2 2 4 2 2 2 2 2
1 2.8 2 1 2 1 1 2 2 2 7 1100 2 PG 16 6 8 55 170 1 1 17 1 2 1 2 2 2 2 2
1 1.5 2 2 2 1 1 2 2 2 5 150 0 PG 8 5 10 58 69 1 1 12 2 2 4 2 2 2 2 2
1 2.8 2 1 2 1 1 2 2 2 7 1100 2 PG 16 6 8 55 170 1 1 17 1 2 1 2 2 2 2 2
1 8 1 2 2 1 2 1 2 2 11 4650 7 PG 12 10 16 13 8297 2 2 20 1 2 3 1 2 2 2 2
1 2 2 1 1 1 1 2 2 2 9 300 2 PG 6 10 11 32 24 1 1 15 2 2 2 2 2 2 2 2
1 2 2 2 1 1 1 2 2 2 5 300 0 PJ 9 6 8 45 349 1 1 12 2 2 1 2 2 2 2 2
1 1.3 2 2 1 1 2 2 1 2 5 600 0 PG 6 4 12 28 21 1 1 16 2 2 2 2 1 2 2 2
1 3 2 2 2 1 1 2 2 2 3 450 2 PG 5 4 7 46 56 1 1 13 2 2 2 2 2 2 2 2
1 2.5 2 2 2 2 1 2 2 2 6 200 2 PG 8 3 9 55 34 1 1 45 2 2 2 2 2 2 2 2
1 4 2 2 2 1 1 2 2 2 6 200 0 PG 7 6 9 42 50 1 1 14 2 2 1 2 2 2 2 2
1 1.5 2 2 2 1 1 2 2 2 5 150 0 PG 8 5 10 58 69 1 1 12 2 2 4 2 2 2 2 2
1 2.8 2 1 2 1 1 2 2 2 7 1100 2 PG 16 6 8 55 170 1 1 17 1 2 1 2 2 2 2 2
1 8 1 2 2 1 2 1 2 2 11 4650 7 PG 12 10 16 13 8297 2 2 20 1 2 3 1 2 2 2 2
1 2 2 1 1 1 1 2 2 2 9 300 2 PG 6 10 11 32 24 1 1 15 2 2 2 2 2 2 2 2
1 2 2 2 1 1 1 2 2 2 5 300 0 PJ 9 6 8 45 349 1 1 12 2 2 1 2 2 2 2 2
1 1.3 2 2 1 1 2 2 1 2 5 600 0 PG 6 4 12 28 21 1 1 16 2 2 2 2 1 2 2 2
1 2.6 2 2 2 2 2 1 2 2 5 80 0 PJ 11 8 14 102 450 1 1 18 1 2 2 1 1 2 2 2
1 2.5 2 2 2 2 1 2 2 2 6 200 2 PG 8 3 9 120 86 1 1 45 2 2 2 2 2 2 2 2
1 4 2 2 2 1 1 2 2 2 4 200 2 PG[D] 6 3 7 83 65 1 1 16 2 2 2 2 1 2 2 2
1 2 2 2 1 2 2 2 2 10 800 2 PG 7 6 8 84 68 1 1 15 2 2 4 2 1 2 2 2
1 2.6 2 2 2 2 2 1 2 2 5 200 0 PJ 8 10 12 96 54 1 1 16 2 2 4 2 2 2 2 2
1 1 2 2 2 1 1 2 2 2 5 250 0 PJ 12 8 14 120 100 1 1 14 1 2 4 1 1 1 2 2
1 1.5 2 1 1 1 1 2 2 2 4.5 100 0 PJ 9 7 10 120 86 1 1 12 2 2 4 2 1 2 2 2
1 2.6 2 2 2 2 2 1 2 2 5 80 0 PJ 11 8 14 102 450 1 1 18 1 2 2 1 1 2 2 2
1 1.1 2 2 2 1 1 2 2 2 5 120 0 PJ 7 5 10 102 50 1 1 12 2 2 4 2 2 2 2 2
1 1.5 2 1 2 1 1 2 2 2 4 80 0 PJ 7 4 9 86 42 1 1 11 2 2 4 2 2 2 2 2
1 1 2 1 1 1 2 2 2 1 6 200 0 PJ 9 4 8 24 36 1 1 14 2 2 4 2 2 2 2 2
1 3 22 2 2 1 1 2 2 2 6 100 0 PJ 8 7 9 40 80 1 1 10 2 2 4 2 2 2 2 2
1 1 2 2 2 1 2 1 2 2 4 100 0 PJ 8 4 9 30 66 1 1 12 2 2 4 2 2 2 2 2
1 2 2 2 2 1 1 2 2 2 6 120 0 PJ 6 8 9 40 36 1 1 12 2 2 4 2 2 2 2 2
1 3 2 2 2 1 2 2 1 2 6 100 0 PJ 7 6 8 32 74 1 1 14 2 2 4 2 2 2 2 2
1 2.2 2 2 2 2 2 2 2 1 6 200 0 PJ 8 5 9 26 58 1 1 13 2 2 4 2 2 2 2 2
1 3.2 2 2 2 2 1 2 2 2 6 200 0 PJ 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
1 2 2 2 1 2 2 2 2 10 800 2 PG 7 6 8 84 68 1 1 15 2 2 4 2 1 2 2 2
1 2.6 2 2 2 2 2 1 2 2 5 200 0 PJ 8 10 12 96 54 1 1 16 2 2 4 2 2 2 2 2
1 1 2 2 2 1 1 2 2 2 5 250 0 PJ 12 8 14 120 100 1 1 14 1 2 4 1 1 1 2 2
1 1.5 2 1 1 1 1 2 2 2 4.5 100 0 PJ 9 7 10 120 86 1 1 12 2 2 4 2 1 2 2 2
1 2.6 2 2 2 2 2 1 2 2 5 80 0 PJ 11 8 14 102 450 1 1 18 1 2 2 1 1 2 2 2
1 1.1 2 2 2 1 1 2 2 2 5 120 0 PJ 7 5 10 102 50 1 1 12 2 2 4 2 2 2 2 2
1 1.5 2 1 2 1 1 2 2 2 4 80 0 PJ 7 4 9 86 42 1 1 11 2 2 4 2 2 2 2 2
1 1 2 1 1 1 2 2 2 1 6 200 0 PJ 9 4 8 24 36 1 1 14 2 2 4 2 2 2 2 2
1 3 22 2 2 1 1 2 2 2 6 100 0 PJ 8 7 9 40 80 1 1 10 2 2 4 2 2 2 2 2
1 1 2 2 2 1 2 1 2 2 4 100 0 PJ 8 4 9 30 66 1 1 12 2 2 4 2 2 2 2 2
1 2 2 2 2 1 1 2 2 2 6 120 0 PJ 6 8 9 40 36 1 1 12 2 2 4 2 2 2 2 2
1 3 2 2 2 1 2 2 1 2 6 100 0 PJ 7 6 8 32 74 1 1 14 2 2 4 2 2 2 2 2
1 2.2 2 2 2 2 2 2 2 1 6 200 0 PJ 8 5 9 26 58 1 1 13 2 2 4 2 2 2 2 2
1 3.2 2 2 2 2 1 2 2 2 6 200 0 PJ 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
1 3 2 2 2 1 2 2 1 2 6 100 0 PJ 7 6 8 32 74 1 1 14 2 2 4 2 2 2 2 2
1 2.2 2 2 2 2 2 2 2 1 6 200 0 PJ 8 5 9 26 58 1 1 13 2 2 4 2 2 2 2 2
1 3.2 2 2 2 2 1 2 2 2 6 200 0 PJ 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
1 2 2 2 2 1 2 1 2 2 6 50 2 PG[D} 6 2 15 510 4059 1 1 36 2 2 A 1 1 2 2 2
1 3 2 2 2 1 2 2 1 2 6 100 0 PJ 7 6 8 32 74 1 1 14 2 2 4 2 2 2 2 2
1 2.2 2 2 2 2 2 2 2 1 6 200 0 PJ 8 5 9 26 58 1 1 13 2 2 4 2 2 2 2 2
1 3.2 2 2 2 2 1 2 2 2 6 200 0 PJ 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
1 3 2 2 2 1 2 2 1 2 6 100 0 PJ 7 6 8 32 74 1 1 14 2 2 4 2 2 2 2 2
1 2.2 2 2 2 2 2 2 2 1 6 200 0 PJ 8 5 9 26 58 1 1 13 2 2 4 2 2 2 2 2
1 3.2 2 2 2 2 1 2 2 2 6 200 0 PJ 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
1 3.2 2 2 2 2 1 2 2 2 6 200 0 PJ 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
1 6 2 2 2 2 1 2 2 2 6 200 2 PG[D] 5 2 5 45 88 1 1 14 2 2 2 2 2 2 2 2
1 3 2 2 2 1 2 2 1 2 6 100 0 PJ 7 6 8 32 74 1 1 14 2 2 4 2 2 2 2 2
1 2.2 2 2 2 2 2 2 2 1 6 200 0 PJ 8 5 9 26 58 1 1 13 2 2 4 2 2 2 2 2
1 3.2 2 2 2 2 1 2 2 2 6 200 0 PJ 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
1 2 2 2 1 2 1 2 2 2 3.5 250 2 PJ[ISO] 7 5 10 33 23 1 1 18 2 2 1 2 2 2 2 2
1 3 2 2 2 2 1 2 2 2 345 3 5 2 5 45 88 1 1 15 2 2 4 2 1 1 2 2
1 3.5 2 2 2 1 1 2 2 2 3.5 350 3 Pj[iso] 7 6 8 32 74 1 1 15 2 2 4 2 2 2 2 2
1 3 2 2 2 2 2 2 1 2 3.5 300 2 8 5 9 26 58 1 1 45 2 2 4 1 2 1 2 2
1 3 2 1 2 1 1 2 2 2 6 150 2 pj[iso] 5 5 5 65 55 1 1 31 2 2 4 2 2 2 2 2
1 2 2 1 1 1 2 2 2 2 3.5 530 0 pj[iso] 4 3 9 24.3 39 1 1 15 2 2 4 2 2 2 2 2
1 2 2 2 2 2 2 1 2 2 4 300 2 pj 7 5 10 33 23 1 1 23 2 2 4 2 2 2 2 1
1 3 2 2 2 2 2 1 2 2 5 340 0 pj 5 2 5 45 88 1 1 12 2 2 4 2 2 1 2 2
1 3.5 2 2 1 2 1 2 2 2 5 300 1 PG[D2M]10 4 10 33 23 1 1 33 1 2 4 2 2 2 2 2
1 5 1 1 2 2 2 2 2 2 5 400 2 pj[isol] 10 12 14 45 88 1 1 12 2 2 2 1 2 2 2 2
1 3 2 2 2 2 1 2 2 2 5 300 1 PJ[iso]d 5 4 5 32 74 1 1 44 2 2 4 2 2 2 2 2
1 2.5 2 2 2 2 2 2 2 1 4 600 1 PJ[iso] 5 3 5 34 20 1 1 41 2 2 4 2 2 2 2 2
1 3 2 2 1 1 2 2 1 2 6 200 2 pj[isol] 7 3 9 100 106 1 1 40 2 2 4 2 2 2 2 2
1 2 2 1 1 2 1 2 2 2 5.5 300 2 pj[isol] 10 5 10 153 656 1 1 57 1 2 1 2 1 2 2 2
1 2.2 2 1 1 1 2 2 2 2 4 300 3 Pj[iso] 6 6 13 44 55 1 1 43 2 2 4 2 1 2 2 2
2 2.5 2 2 2 2 2 2 2 2 5 300 2 pj[isol] 7 4 11 45 54 1 1 6 2 2 4 1 1 2 2 1
2 2.5 2 2 1 2 1 2 2 2 4 500 1 PJ[iso]dtm21 6 9 1000 5000 1 1 12 1 2 2 2 1 2 2 2
2 2.5 2 2 2 2 1 2 2 2 5 300 2 PJ[ISOL] 7 4 10 33 23 1 1 5 2 2 3 2 1 2 2 1
1 3 2 2 2 2 2 2 2 2 6 150 0 Pj[isol] 12 3 14 45 88 1 1 27 1 2 2 2 1 2 2 2
1 3 2 1 1 2 2 2 1 2 5 200 2 PJ[ISOL] 6 4 5 32 74 1 1 5 2 2 4 2 2 2 2 1
1 3.5 2 2 2 2 2 2 2 1 4 250 2 PG[DTM]7 5 7 33 45 1 1 12 2 2 4 2 2 1 2 2
1 3 2 2 1 2 2 2 2 2 4 200 2 Pg[DTM]5 3 7 78 139 1 1 12 2 2 4 2 2 2 2 2
1 3 2 2 1 2 2 2 2 2 4 200 2 Pg[DTM]5 3 7 78 139 1 1 12 2 2 4 2 2 2 2 2
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